{"content":"<li class=\"n-box-item date-title\" data-end=\"1507867199\" data-start=\"1507780800\" data-txt=\"Monday, December 23, 2019\">Thursday, October 12, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3300829\" data-ts=\"1507850802\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIA\" target=\"_blank\">VIA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300829-guggenheim-cuts-amcx-via-dis-tv-sheds-subscribers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Guggenheim cuts AMCX, VIA, DIS as TV sheds subscribers</a></h4><ul>   <li>In a week growing tough for media stocks, Guggenheim has cut ratings on AMC Networks (<a href=\"http://seekingalpha.com/symbol/AMCX\" target=\"_blank\">AMCX</a> <font color='red'>-6.8%</font>), Viacom (<a href='https://seekingalpha.com/symbol/VIA' title='Viacom Inc.'>VIA</a> <font color='red'>-3.4%</font>, <a href='https://seekingalpha.com/symbol/VIAB' title='Viacom Inc.'>VIAB</a> <font color='red'>-2.5%</font>) and Disney (<a href=\"http://seekingalpha.com/symbol/DIS\" target=\"_blank\">DIS</a> <font color='red'>-1.6%</font>) amid talk of hot competition in an environment where pay TV continues to lose subscribers (see <a href=\"https://seekingalpha.com/news/3300564-t-filing-natural-disasters-hitting-earnings-directv-now-300k-adds\" target=\"_blank\">AT&amp;T's preliminary announcement</a>, for example).</li>    <li>The firm's cut its Buy rating on all three to Neutral. With regard to AMC, it's cautious on ad growth and expects digital video competitors to amp up competition; the firm trimmed its price target to $60 from $73, implying 11.6% upside from here.</li>    <li>Viacom is faces challenges from fees getting revised downward and carriage losses, and Guggenheim notes its channels aren't on Hulu, YouTube or Sony Vue. It's cut that price target to $25 from $37; shares closed at $24.57 today.</li>    <li>As for Disney, recent trends in domestic subscribers and advertising have been weak, and investors may look down on initial investments and long lead times in the company's direct-to-consumer video plans. Guggenheim has trimmed that price target to $102 from $122, implying 5.2% upside from here.</li>    <li>Source: Bloomberg</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300829\" data-linked=\"Guggenheim cuts AMCX, VIA, DIS as TV sheds subscribers\" data-tweet=\"$VIA $VIA $VIAB - Guggenheim cuts AMCX, VIA, DIS as TV sheds subscribers https://seekingalpha.com/news/3300829-guggenheim-cuts-amcx-via-dis-tv-sheds-subscribers?source=tweet\" data-url=\"https://seekingalpha.com/news/3300829-guggenheim-cuts-amcx-via-dis-tv-sheds-subscribers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>35&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300828\" data-ts=\"1507847977\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DISCA\" target=\"_blank\">DISCA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300828-tv-firms-gathering-on-ad-measurement-initiative\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TV firms gathering on ad-measurement initiative</a></h4><ul>   <li>Several TV companies are coming together Friday, <i>Variety</i> reports, on a high-profile project to <a href=\"http://variety.com/2017/tv/news/thor-tv-media-measurement-advertising-1202588598/\" target=\"_blank\">redefine measurement of ad success or failure</a>, based more on purchase action rather than ad visibility.</li>    <li>Among the companies said to be meeting on their still-young Project \"Thor\": Discovery Communications (<a href=\"http://seekingalpha.com/symbol/DISCA\" target=\"_blank\">DISCA</a> <font color='red'>-3.6%</font>), Turner (<a href=\"http://seekingalpha.com/symbol/TWX\" target=\"_blank\">TWX</a> <font color='red'>-1.9%</font>), CBS (<a href=\"http://seekingalpha.com/symbol/CBS\" target=\"_blank\">CBS</a> <font color='red'>-1%</font>), NBCUniversal (<a href=\"http://seekingalpha.com/symbol/CMCSA\" target=\"_blank\">CMCSA</a> <font color='red'>-3.9%</font>) and A&amp;E (co-owned by Walt Disney (<a href=\"http://seekingalpha.com/symbol/DIS\" target=\"_blank\">DIS</a> <font color='red'>-1.6%</font>) and Hearst), as well as the trade group Video Advertising Bureau.</li>    <li>Set-top box data could play a part in finding when ads ran and how they might have affected a purchase decision. Most networks continue to get the bulk of ad revenue based on linear viewers despite a landscape shifting to video on demand and device-based watching.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300828\" data-linked=\"TV firms gathering on ad-measurement initiative\" data-tweet=\"$DISCA $DISCA $TWX - TV firms gathering on ad-measurement initiative https://seekingalpha.com/news/3300828-tv-firms-gathering-on-ad-measurement-initiative?source=tweet\" data-url=\"https://seekingalpha.com/news/3300828-tv-firms-gathering-on-ad-measurement-initiative\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300826\" data-ts=\"1507847207\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PXD\" target=\"_blank\">PXD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300826-pioneer-naturals-q3-production-rises-6-q-q-despite-harvey\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pioneer Natural&#39;s Q3 production rises 6% Q/Q despite Harvey</a></h4><ul>     <li>Pioneer Natural Resources (NYSE:<a href='https://seekingalpha.com/symbol/PXD' title='Pioneer Natural Resources Company'>PXD</a>) earlier reported <a href=\"https://seekingalpha.com/pr/16966739-pioneer-natural-resources-company-announces-third-quarter-production-realizations\" target=\"_blank\">Q3 production rose 6% Q/Q</a> to 276K boe/day, even while coping with downtime from shut-ins and midstream issues related to Hurricane Harvey.</li>     <li>PXD says natural gas production, which took the biggest hit from Harvey, fell 4% Q/Q to 340M cf/day, but oil production jumped 10% to an all-time high of 162K bbl/day, led by the Permian Basin&rsquo;s Spraberry and Wolfcamp plays; natural gas liquids output also rose 7.5% to 57,346 bbl/day.</li>          <li>PXD says Harvey caused the loss of 3,500 boe/day overall in the quarter, but adjusted for the losses, production would have been at the top end of guidance of 274K-279K boe/day.</li><li>Shares fell 1.8% in today's trade, along with most oil and gas stocks as crude oil prices fell, but PXD&nbsp;<font color='green'>+1.9%</font> after-hours.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300826\" data-linked=\"Pioneer Natural&#39;s Q3 production rises 6% Q/Q despite Harvey\" data-tweet=\"$PXD - Pioneer Natural&#39;s Q3 production rises 6% Q/Q despite Harvey https://seekingalpha.com/news/3300826-pioneer-naturals-q3-production-rises-6-q-q-despite-harvey?source=tweet\" data-url=\"https://seekingalpha.com/news/3300826-pioneer-naturals-q3-production-rises-6-q-q-despite-harvey\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300823\" data-ts=\"1507845429\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DIS\" target=\"_blank\">DIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300823-bloomberg-disney-cutting-200-from-tv-group\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bloomberg: Disney cutting about 200 from TV group</a></h4><ul>   <li>Disney (<a href=\"http://seekingalpha.com/symbol/DIS\" target=\"_blank\">DIS</a> <font color='red'>-1.6%</font>) is realigning its TV business and <a href=\"https://www.bloomberg.com/news/articles/2017-10-12/disney-is-said-to-cut-200-jobs-from-its-tv-networks-division\" target=\"_blank\">cutting about 200 jobs</a> at ABC and its cable nets, Bloomberg reports.</li>    <li>The cuts will give ESPN a miss, focusing on its entertainment networks. The company's shifting resources as part of an adaptation to the shrinking traditional-TV audience, according to the report.</li>    <li>The job cuts will mostly fall on operations, such as finance.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300823\" data-linked=\"Bloomberg: Disney cutting about 200 from TV group\" data-tweet=\"$DIS - Bloomberg: Disney cutting about 200 from TV group https://seekingalpha.com/news/3300823-bloomberg-disney-cutting-200-from-tv-group?source=tweet\" data-url=\"https://seekingalpha.com/news/3300823-bloomberg-disney-cutting-200-from-tv-group\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>30&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300820\" data-ts=\"1507844198\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWX\" target=\"_blank\">TWX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300820-bloomberg-and-t-considers-public-offering-for-latin-pay-tv-assets\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bloomberg: AT&amp;T considers public offering for Latin pay TV assets</a></h4><ul>   <li>AT&amp;T (<a href=\"http://seekingalpha.com/symbol/T\" target=\"_blank\">T</a> <font color='red'>-6.1%</font>) is considering a possible public offering of its Latin American pay TV assets, Bloomberg reports, in a move that would provide funds to pay down debt as the company works to swallow Time Warner (NYSE:<a href='https://seekingalpha.com/symbol/TWX' title='Time Warner Inc.'>TWX</a>).</li>    <li>Reuters had reported last month that the company was <a href=\"https://seekingalpha.com/news/3295904-reuters-t-considering-divesting-latin-america-pay-tv\" target=\"_blank\">considering a move that could bring $8B</a>, against debt that would balloon to $180B after the takeover.</li>    <li>A source tells Bloomberg that the public market might value the business at $8B-$10B depending on exactly which assets were included in the share offering.</li>    <li>AT&amp;T's not thought to be floating its pay TV business in Mexico, a country where it's been investing more heavily in wireless operations.</li>    <li>Shares slid today in their worst day in nine years, to hover just a bit over the stock's 52-week low -- $35.10, marked on Sept. 8 -- after its preliminary results showed heavy cord-cutting in its linear TV subs.</li>    <li>After hours: <a href='https://seekingalpha.com/symbol/T' title='AT&T Inc.'>T</a> <font color='green'>+0.4%</font>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3300564-t-filing-natural-disasters-hitting-earnings-directv-now-300k-adds\" target=\"_blank\">AT&amp;T filing: Natural disasters hitting earnings; DirecTV Now at 300K adds</a> (Oct. 11 2017)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300820\" data-linked=\"Bloomberg: AT&amp;T considers public offering for Latin pay TV assets\" data-tweet=\"$TWX $TWX $T - Bloomberg: AT&amp;T considers public offering for Latin pay TV assets https://seekingalpha.com/news/3300820-bloomberg-and-t-considers-public-offering-for-latin-pay-tv-assets?source=tweet\" data-url=\"https://seekingalpha.com/news/3300820-bloomberg-and-t-considers-public-offering-for-latin-pay-tv-assets\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>67&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300819\" data-ts=\"1507844150\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300819-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/EXFO' title='EXFO Inc.'>EXFO</a> <font color='green'>+12.3%</font>. <a href='https://seekingalpha.com/symbol/FINL' title='The Finish Line, Inc.'>FINL</a> <font color='green'>+6.4%</font>. <a href='https://seekingalpha.com/symbol/ONCE' title='Spark Therapeutics'>ONCE</a> <font color='green'>+6.4%</font>. <a href='https://seekingalpha.com/symbol/GPS' title='The Gap, Inc.'>GPS</a> <font color='green'>+4.5%</font>. <a href='https://seekingalpha.com/symbol/SIG' title='Signet Jewelers Limited'>SIG</a> <font color='green'>+4.1%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/TNDM' title='Tandem Diabetes Care, Inc.'>TNDM</a> <font color='red'>-25.2%</font>. <a href='https://seekingalpha.com/symbol/AAOI' title='Applied Optoelectronics, Inc.'>AAOI</a> <font color='red'>-16.8%</font>. <a href='https://seekingalpha.com/symbol/ECYT' title='Endocyte, Inc.'>ECYT</a> <font color='red'>-8.9%</font>. <a href='https://seekingalpha.com/symbol/AXTI' title='AXT Inc'>AXTI</a> <font color='red'>-4.9%</font>. <a href='https://seekingalpha.com/symbol/INFI' title='Infinity Pharmaceuticals, Inc.'>INFI</a> <font color='red'>-4.0%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300819\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$EXFO $FINL $ONCE - After Hours Gainers / Losers https://seekingalpha.com/news/3300819-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3300819-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300817\" data-ts=\"1507843508\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATRS\" target=\"_blank\">ATRS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300817-antares-pharmaminus-30-fda-finds-deficiencies-in-xyosted-nda\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Antares Pharma -30% as FDA finds deficiencies in Xyosted NDA</a></h4><ul>     <li>Antares Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/ATRS' title='Antares Pharma Inc.'>ATRS</a>) <font color='red'>-29.7%</font>&nbsp;after-hours on news that the FDA had <a href=\"https://seekingalpha.com/pr/16967669-antares-pharma-provides-xyosted-regulatory-update\" target=\"_blank\">identified deficiencies</a> as part of a review of the company&rsquo;s new drug application for Xyosted (testosterone enanthate).</li>     <li>ATRS says the FDA did not specify the deficiencies but would prevent continuing with labeling and postmarketing requirements and commitments.</li><li>ATRS first submitted the Xyosted NDA in December 2016.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300817\" data-linked=\"Antares Pharma -30% as FDA finds deficiencies in Xyosted NDA\" data-tweet=\"$ATRS - Antares Pharma -30% as FDA finds deficiencies in Xyosted NDA https://seekingalpha.com/news/3300817-antares-pharmaminus-30-fda-finds-deficiencies-in-xyosted-nda?source=tweet\" data-url=\"https://seekingalpha.com/news/3300817-antares-pharmaminus-30-fda-finds-deficiencies-in-xyosted-nda\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>106&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300815\" data-ts=\"1507842888\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ONCE\" target=\"_blank\">ONCE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300815-spark-therapeutics-resumes-trading-up-6_4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Spark Therapeutics resumes trading up 6.4%</a></h4><ul>   <li>Spark Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ONCE' title='Spark Therapeutics'>ONCE</a>) has resumed trading <font color='green'>up 6.4%</font> following a <a href=\"https://seekingalpha.com/news/3300746-ad-com-backs-sparks-luxturna-gene-therapy-type-retinal-dystrophy\" target=\"_blank\">unanimous FDA advisory committee vote</a> in favor of approving the company's treatment for mutation-associated retinal dystrophy.</li>    <li>The panel voted 16-0 in favor of Luxturna (voretigene neparvovec).</li>    <li>Shares are quoting at what would be a new all-time high.</li><li>Trading had been suspended since before today's market open, with the panel vote on the docket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300815\" data-linked=\"Spark Therapeutics resumes trading up 6.4%\" data-tweet=\"$ONCE - Spark Therapeutics resumes trading up 6.4% https://seekingalpha.com/news/3300815-spark-therapeutics-resumes-trading-up-6_4?source=tweet\" data-url=\"https://seekingalpha.com/news/3300815-spark-therapeutics-resumes-trading-up-6_4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300808\" data-ts=\"1507841495\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ECYT\" target=\"_blank\">ECYT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300808-endocyte-registers-150m-mixed-shelf-offering-shares-slip-2-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Endocyte registers $150M mixed shelf offering; shares slip 2% after hours</a></h4><ul><li>Endocyte (NASDAQ:<a href='https://seekingalpha.com/symbol/ECYT' title='Endocyte, Inc.'>ECYT</a>) is down&nbsp;<font color='red'>2%</font>&nbsp;after hours on light volume on the heels of its <a href=\"https://www.sec.gov/Archives/edgar/data/1235007/000155837017007346/s-3.htm\" target=\"_blank\">S-3</a> filing for a $150M mixed shelf offering. Proceeds will be used for general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300808\" data-linked=\"Endocyte registers $150M mixed shelf offering; shares slip 2% after hours\" data-tweet=\"$ECYT - Endocyte registers $150M mixed shelf offering; shares slip 2% after hours https://seekingalpha.com/news/3300808-endocyte-registers-150m-mixed-shelf-offering-shares-slip-2-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3300808-endocyte-registers-150m-mixed-shelf-offering-shares-slip-2-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:51 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300785\" data-ts=\"1507840206\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NEO\" target=\"_blank\">NEO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300785-neogenomics-sees-q3-revenue-of-63_1m-2_8m-shy-of-consensus-shares-ease-1-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NeoGenomics sees Q3 revenue of $63.1M, $2.8M shy of consensus; shares ease 1% after hours</a></h4><ul><li>On a <a href=\"https://seekingalpha.com/pr/16967504-neogenomics-announces-preliminary-quarter-3-results-financial-impacts-hurricanes-summary\" target=\"_blank\">preliminary basis</a>, NeoGenomics (NASDAQ:<a href='https://seekingalpha.com/symbol/NEO' title='NeoGenomics Inc.'>NEO</a>) expects Q3 revenue of $63.1M, up 4% yoy but shy of consensus of $65.9M.</li><li>Non-GAAP EBITDA should be ~$6.0M. Clinical genetic test volume should be ~162.5K.</li><li>The company says Hurricanes Harvey and Irma depressed revenue $1.0M and non-GAAP EBITDA $1.2M in the quarter. It also expects to record a one-time $1.3M charge to revenue to reflect a change in the process for estimating revenue for unbilled tests at quarter-end.</li><li>Q3 revenue will be ~$1.3M less than Q2 as a result of the PathLogic divestiture.</li><li><strong>Preliminary Q4 guidance</strong>: Revenue: $65M - 67M; non-GAAP EBITDA: $9M - 10M.</li><li>Shares are down&nbsp;<font color='red'>1%</font>&nbsp;after hours on increased volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300785\" data-linked=\"NeoGenomics sees Q3 revenue of $63.1M, $2.8M shy of consensus; shares ease 1% after hours\" data-tweet=\"$NEO - NeoGenomics sees Q3 revenue of $63.1M, $2.8M shy of consensus; shares ease 1% after hours https://seekingalpha.com/news/3300785-neogenomics-sees-q3-revenue-of-63_1m-2_8m-shy-of-consensus-shares-ease-1-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3300785-neogenomics-sees-q3-revenue-of-63_1m-2_8m-shy-of-consensus-shares-ease-1-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300783\" data-ts=\"1507839436\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BTX\" target=\"_blank\">BTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300783-biotime-readies-stock-offering-shares-down-3-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioTime readies stock offering; shares down 3% after hours</a></h4><ul><li>Thinly traded micro cap BioTime (NYSEMKT:<a href='https://seekingalpha.com/symbol/BTX' title='BioTime, Inc'>BTX</a>) slips&nbsp;<font color='red'>3%</font>&nbsp;after hours on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16967527-biotime-inc-announces-proposed-public-offering-common-stock\" target=\"_blank\">planned public offering</a> of common stock. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300783\" data-linked=\"BioTime readies stock offering; shares down 3% after hours\" data-tweet=\"$BTX $LCTX - BioTime readies stock offering; shares down 3% after hours https://seekingalpha.com/news/3300783-biotime-readies-stock-offering-shares-down-3-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3300783-biotime-readies-stock-offering-shares-down-3-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300777\" data-ts=\"1507839099\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TNDM\" target=\"_blank\">TNDM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300777-tandem-diabetes-care-readies-equity-offering-shares-down-23-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tandem Diabetes Care readies equity offering; shares down 23% after hours</a></h4><ul><li>Thinly traded nano cap Tandem Diabetes Care (NASDAQ:<a href='https://seekingalpha.com/symbol/TNDM' title='Tandem Diabetes Care, Inc.'>TNDM</a>) slumps&nbsp;<font color='red'>23%</font>&nbsp;after hours on robust volume in response to its <a href=\"https://seekingalpha.com/pr/16967505-tandem-diabetes-care-announces-proposed-underwritten-public-offering-common-stock-series\" target=\"_blank\">planned public offering</a> of stock and warrants. Prices, volumes and terms have yet to be released.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300777\" data-linked=\"Tandem Diabetes Care readies equity offering; shares down 23% after hours\" data-tweet=\"$TNDM - Tandem Diabetes Care readies equity offering; shares down 23% after hours https://seekingalpha.com/news/3300777-tandem-diabetes-care-readies-equity-offering-shares-down-23-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3300777-tandem-diabetes-care-readies-equity-offering-shares-down-23-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300774\" data-ts=\"1507838724\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAOI\" target=\"_blank\">AAOI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300774-applied-optoelectronics-releases-downbeat-preliminary-q3-results-updated\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Applied Optoelectronics releases downbeat preliminary Q3 results (updated)</a></h4><ul>     <li>Applied Optoelectronics (<a href=\"http://seekingalpha.com/symbol/AAOI\" target=\"_blank\">AAOI</a> <font color='red'>-4.2%</font>) has been halted for news pending.</li>     <li>Declines during market hours today wiped out gains of the past two days.</li>   <li><b>Updated 4:09 p.m.:</b> The company has <a href=\"https://seekingalpha.com/pr/16967538-applied-optoelectronics-announces-preliminary-third-quarter-2017-results\" target=\"_blank\">announced some preliminary Q3 results</a>, which \"fell short of prior estimates and were negatively impacted by lower than expected sales to one of our large datacenter customers. Despite this shortfall, we maintained a strong gross margin profile in the quarter, and continued to experience solid demand with our other top datacenter customers.\"</li>    <li>It's announcing revenue of $88M-$89M, down from its previous outlook for $107M-$115M (and consensus for $111.5M); gross margin in the range of 43.5%-44.5%, and non-GAAP EPS of $1.04-$1.09 -- down from previous forecasts for $1.30-$1.43 (and below consensus for $1.31).</li>    <li>It's <a href=\"http://investors.ao-inc.com/\" target=\"_blank\">holding a conference call</a> to discuss these preliminary results at 4:30 p.m. ET.</li><li>Applied Opto will resume after-hours trading at 4:35 p.m.</li><li><strong>Updated:</strong>&nbsp;After resuming trading, shares closed out the postmarket session <font color='red'>down 19.9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300774\" data-linked=\"Applied Optoelectronics releases downbeat preliminary Q3 results (updated)\" data-tweet=\"$AAOI - Applied Optoelectronics releases downbeat preliminary Q3 results (updated) https://seekingalpha.com/news/3300774-applied-optoelectronics-releases-downbeat-preliminary-q3-results-updated?source=tweet\" data-url=\"https://seekingalpha.com/news/3300774-applied-optoelectronics-releases-downbeat-preliminary-q3-results-updated\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:05 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>275&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300770\" data-ts=\"1507838324\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FET\" target=\"_blank\">FET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300770-forum-energy-guides-q3-lower-on-hurricane-impacts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Forum Energy guides Q3 lower on hurricane impacts</a></h4><ul>     <li>Forum Energy Technologies (<a href='https://seekingalpha.com/symbol/FET' title='Forum Energy Technologies'>FET</a> <font color='red'>-6.7%</font>) plunges after issuing <a href=\"https://seekingalpha.com/pr/16966322-forum-energy-technologies-announces-effect-hurricane-harvey-updates-third-quarter-2017\" target=\"_blank\">downside Q3 guidance</a>, expecting a $0.10/share loss vs. analyst consensus for a $0.06 loss, and ~$200M in revenues vs. $221M consensus.</li><li>FET says it was hurt by temporarily idled facilities and operations directly  related to Hurricane Harvey, which resulted in foregone revenue and  under-absorption of manufacturing costs, as well as the  indirect effect of customer, supplier and logistical delays.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300770\" data-linked=\"Forum Energy guides Q3 lower on hurricane impacts\" data-tweet=\"$FET - Forum Energy guides Q3 lower on hurricane impacts https://seekingalpha.com/news/3300770-forum-energy-guides-q3-lower-on-hurricane-impacts?source=tweet\" data-url=\"https://seekingalpha.com/news/3300770-forum-energy-guides-q3-lower-on-hurricane-impacts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:58 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300764\" data-ts=\"1507836339\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JONE\" target=\"_blank\">JONE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300764-jones-energyminus-9-shareholder-sells-465k-shares-in-week\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jones Energy -9% as shareholder sells 465K shares in a week</a></h4><ul>     <li>Jones Energy (<a href='https://seekingalpha.com/symbol/JONE' title='Jones Energy, Inc.'>OTC:JONE</a> <font color='red'>-8.9%</font>) plunges after major shareholder Metalmark Capital II disclosed it sold 38.8K shares earlier this week from its investment vehicles at an average of $1.61/share, according to a new <a href=\"https://www.streetinsider.com/SEC+Filings/Form+4+Metalmark+Capital+II+For%3A+Oct+09+Filed+by%3A+Jones+Energy%2C+Inc./13381928.html\" target=\"_blank\">SEC filing</a> last night.</li>     <li>It is Metalmark's <a href=\"https://stocknewstimes.com/2017/10/12/jones-energy-inc-jone-major-shareholder-metalmark-capital-ii-llc-sells-124212-shares.html\" target=\"_blank\">fourth sizable sale</a> of Jones shares in little more than a week, after selling 143K shares on Oct. 4, nearly 158K shares on Oct. 5 and more than 124K shares on Oct. 6.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300764\" data-linked=\"Jones Energy -9% as shareholder sells 465K shares in a week\" data-tweet=\"$JONE - Jones Energy -9% as shareholder sells 465K shares in a week https://seekingalpha.com/news/3300764-jones-energyminus-9-shareholder-sells-465k-shares-in-week?source=tweet\" data-url=\"https://seekingalpha.com/news/3300764-jones-energyminus-9-shareholder-sells-465k-shares-in-week\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:25 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300746\" data-ts=\"1507836107\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ONCE\" target=\"_blank\">ONCE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300746-ad-com-backs-sparks-luxturna-gene-therapy-for-type-of-retinal-dystrophy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ad Com backs Spark&#39;s Luxturna gene therapy for type of retinal dystrophy</a></h4><ul><li>The FDA's Cellular, Tissue and Gene Therapies Advisory Committee votes 16 - 0 in favor of approval for Spark Therapeutics' (<a href='https://seekingalpha.com/symbol/ONCE' title='Spark Therapeutics'>ONCE</a>) LUXTURNA (voretigene neparvovec) for the treatment of RPE65 mutation-associated retinal dystrophy.</li><li>The FDA's action date is January 12, 2018.</li><li>Trading should resume later today.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300746\" data-linked=\"Ad Com backs Spark&#39;s Luxturna gene therapy for type of retinal dystrophy\" data-tweet=\"$ONCE - Ad Com backs Spark&#39;s Luxturna gene therapy for type of retinal dystrophy https://seekingalpha.com/news/3300746-ad-com-backs-sparks-luxturna-gene-therapy-for-type-of-retinal-dystrophy?source=tweet\" data-url=\"https://seekingalpha.com/news/3300746-ad-com-backs-sparks-luxturna-gene-therapy-for-type-of-retinal-dystrophy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:21 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300762\" data-ts=\"1507835990\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INFI\" target=\"_blank\">INFI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300762-infinity-pharma-up-big-news-scarce-shares-ahead-90\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Infinity Pharma up big but news scarce; shares ahead 90%</a></h4><ul><li>Micro cap Infinity Pharmaceuticals (<a href='https://seekingalpha.com/symbol/INFI' title='Infinity Pharmaceuticals, Inc.'>INFI</a> <font color='green'>+90.4%</font>) joins the long list of biotech breakouts on a whopping 43x surge in volume. No specific news accounts for the abnormally heavy accumulation. Two items from earlier today have helped:</li><li>Wells Fargo upgraded the stock to Outperform.</li><li>The <a href=\"https://seekingalpha.com/pr/16966573-infinity-announces-ipiminus-549-late-breaking-presentation-sitc-annual-meeting\" target=\"_blank\">announcement </a>of new data on lead candidate IPI-549 to be presented on November 10 at the 2017 Society for Immunotherapy of Cancer Annual Meeting in National Harbor, MD. A \"clinical trials in progress\" poster will also be presented related to its Phase 1/1b study of IPI-549 as monotherapy and in combination with Bristol-Myers Squibb's Opdivo (nivolumab) in advanced solid tumors.</li><li><a href=\"http://www.infi.com/home/research-development/pi3k/\" target=\"_blank\">IPI-549</a>&nbsp;is an orally available inhibitor of an enzyme called phosphoinositide-3-kinase (PI3K)-gamma that plays a key role in inflammation, immunity and cancer. The company believes it is the only PI3K-gamma inhibitor in clinical development.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3297325-infinity-pharma-bristol-myers-squibb-add-tnbc-patients-clinical-evaluation-ipiminus-549\" target=\"_blank\">Infinity Pharma and Bristol-Myers Squibb add TNBC patients to clinical evaluation of IPI-549 and Opdivo</a> (Sept. 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3300762\" data-linked=\"Infinity Pharma up big but news scarce; shares ahead 90%\" data-tweet=\"$INFI - Infinity Pharma up big but news scarce; shares ahead 90% https://seekingalpha.com/news/3300762-infinity-pharma-up-big-news-scarce-shares-ahead-90?source=tweet\" data-url=\"https://seekingalpha.com/news/3300762-infinity-pharma-up-big-news-scarce-shares-ahead-90\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300760\" data-ts=\"1507834864\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SKYAY\" target=\"_blank\">SKYAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300760-bt-sky-see-soccer-ratings-rise-digital-firms-wait-in-wings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BT, Sky see soccer ratings rise as digital firms wait in wings</a></h4><ul>   <li>Early ratings for Premier League soccer are <a href=\"https://www.bloomberg.com/news/articles/2017-10-12/premier-league-soccer-gains-viewers-in-season-start-on-sky-bt\" target=\"_blank\">on the upswing</a> ahead of what's likely to be an expensive auction of new rights for the UK.</li>    <li>Sky (<a href=\"http://seekingalpha.com/symbol/SKYAY\" target=\"_blank\">SKYAY</a> <font color='green'>+2.1%</font>) is seeing 8% Y/Y gains, to 819,000 viewers per match, according to Enders Analysis. BT Group (<a href=\"http://seekingalpha.com/symbol/BT\" target=\"_blank\">BT</a> <font color='green'>+0.9%</font>) is up 9%, to 692,000 per match. The numbers are a healthy rebound from last year, which started poorly and ended up down 10%.</li>    <li>That's good news for the league as it gets ready to press more competition for its rights with hopeful new entrants in Facebook (FB  <font color='green'>+0.2%</font>) and Amazon.com (<a href=\"http://seekingalpha.com/symbol/AMZN\" target=\"_blank\">AMZN</a> <font color='green'>+0.7%</font>).</li>    <li>Soccer is key for Sky, which has rights to most games in the league, and it and BT were under investor scrutiny for paying heavily for the rights (which so far seems to be paying off).</li>    <li>Earlier this month, Facebook said it was interested in live rights but hadn't yet committed to bidding on Premier League matches.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300760\" data-linked=\"BT, Sky see soccer ratings rise as digital firms wait in wings\" data-tweet=\"$SKYAY $SKYAY $BT - BT, Sky see soccer ratings rise as digital firms wait in wings https://seekingalpha.com/news/3300760-bt-sky-see-soccer-ratings-rise-digital-firms-wait-in-wings?source=tweet\" data-url=\"https://seekingalpha.com/news/3300760-bt-sky-see-soccer-ratings-rise-digital-firms-wait-in-wings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300758\" data-ts=\"1507834786\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KR\" target=\"_blank\">KR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300758-analysts-warm-up-to-kroger\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts warm up to Kroger</a></h4><ul><li>Pivotal Research hikes its rating on Kroger (<a href='https://seekingalpha.com/symbol/KR' title='Kroger Co.'>KR</a> <font color='green'>+0.7%</font>) to Buy from Hold.</li><li>Stephens bumps Kroger up to an Equalweight rating from Underweight.</li><li>Shares of Kroger are up above 4% since the company boosted its EPS guidance above consensus estimates.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3300406-kroger-rallies-strategy-reset-announced\" target=\"_blank\">Kroger rallies after strategy reset announced</a> (Oct. 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3300758\" data-linked=\"Analysts warm up to Kroger\" data-tweet=\"$KR - Analysts warm up to Kroger https://seekingalpha.com/news/3300758-analysts-warm-up-to-kroger?source=tweet\" data-url=\"https://seekingalpha.com/news/3300758-analysts-warm-up-to-kroger\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300757\" data-ts=\"1507834577\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300757-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/POLA' title='Polar Power Inc'>POLA</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/GLUU' title='Glu Mobile Inc.'>GLUU</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/ISDR' title='Issuer Direct Corp.'>ISDR</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/BLIN' title='Bridgeline Digital, Inc.'>BLIN</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/SMSI' title='Smith Micro Software, Inc.'>SMSI</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='red'>-30%</font>. WPCS <font color='red'>-17%</font>. IFON <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/JMU' title='JMU Limited'>JMU</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/ANY' title='Sphere 3D Corp.'>ANY</a> <font color='red'>-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300757\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$POLA $GLUU $ISDR - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3300757-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3300757-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300756\" data-ts=\"1507834001\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HMNY\" target=\"_blank\">HMNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300756-drama-helios-and-matheson-analytics\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More drama with Helios and Matheson Analytics</a></h4><ul>     <li>Citron Research <a href=\"https://twitter.com/CitronResearch/status/918546790550515713\" target=\"_blank\">tweets</a> that it's covering its short position on Helios and Matheson Analytics (<a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='red'>-31%</font>) after catching the negative price action it anticipated in just one day.</li><li>For those jumping late to the HMNY drama, shares skyrocketed 1000% in just a few months on investor hopes for MoviePass before today's stumble.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3300433-rally-continues-helios-and-matheson-analytics\" target=\"_blank\">Rally continues for Helios &amp; Matheson Analytics</a> (Oct. 11)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3300666-make-moviepass\" target=\"_blank\">What to make of MoviePass?</a> (Oct. 12)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300756\" data-linked=\"More drama with Helios and Matheson Analytics\" data-tweet=\"$HMNY - More drama with Helios and Matheson Analytics https://seekingalpha.com/news/3300756-drama-helios-and-matheson-analytics?source=tweet\" data-url=\"https://seekingalpha.com/news/3300756-drama-helios-and-matheson-analytics\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>50&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300754\" data-ts=\"1507833267\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PCG\" target=\"_blank\">PCG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300754-pg-and-e-plunges-report-links-downed-power-lines-to-california-fires\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PG&amp;E plunges as report links downed power lines to California fires</a></h4><ul>     <li>PG&amp;E (<a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a> <font color='red'>-3.7%</font>) shares are under pressure in the wake of a <em>San Jose Mercury News</em> report of a <a href=\"http://www.mercurynews.com/2017/10/10/pge-power-lines-linked-to-wine-country-fires/\" target=\"_blank\">possible link</a> between the outburst of <a href=\"https://seekingalpha.com/news/3300128-california-fires-scorch-wine-country-pg-and-e-says-100k-customers-without-power\" target=\"_blank\">wildfires in northern California</a> to downed power lines.</li>     <li>State fire officials say they are still investigating the cause of the inferno that has killed 17 people and destroyed more than 2K, but the report says power equipment failures have turned a spotlight on PG&amp;E, raising questions about how well the utility has maintained its equipment in the area and whether it adequately cut back trees from power lines to reduce fire risk.</li>     <li>PG&amp;E issued a statement last night acknowledging the equipment troubles but called questions about maintenance &ldquo;highly speculative.&rdquo;</li>     <li>Large California utilities including PG&amp;E \"have a long history of being found responsible for major wildfires because of inadequate maintenance of their power lines,\" according to the report.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300754\" data-linked=\"PG&amp;E plunges as report links downed power lines to California fires\" data-tweet=\"$PCG - PG&amp;E plunges as report links downed power lines to California fires https://seekingalpha.com/news/3300754-pg-and-e-plunges-report-links-downed-power-lines-to-california-fires?source=tweet\" data-url=\"https://seekingalpha.com/news/3300754-pg-and-e-plunges-report-links-downed-power-lines-to-california-fires\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300750\" data-ts=\"1507831855\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/H\" target=\"_blank\">H</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300750-hyatt-turns-lower-on-report-of-another-data-breach\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hyatt turns lower on report of another data breach</a></h4><ul><li><a href=\"https://krebsonsecurity.com/\" target=\"_blank\">via Krebs on Security</a></li><li>Hyatt (NYSE:<a href='https://seekingalpha.com/symbol/H' title='Hyatt Hotels Corporation'>H</a>) says it discovered sings of unauthorized access to payment card information from cards manually entered or swiped at the front desk of certain locations between mid-March and early July of this year.</li><li>Shares were in the green prior to the news, but now<font color='red'> lower by 0.1%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300750\" data-linked=\"Hyatt turns lower on report of another data breach\" data-tweet=\"$H - Hyatt turns lower on report of another data breach https://seekingalpha.com/news/3300750-hyatt-turns-lower-on-report-of-another-data-breach?source=tweet\" data-url=\"https://seekingalpha.com/news/3300750-hyatt-turns-lower-on-report-of-another-data-breach\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:10 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300748\" data-ts=\"1507831395\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GEL\" target=\"_blank\">GEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300748-genesis-energy-down-3-after-distribution-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Genesis Energy down more than 3% after distribution cut</a></h4><ul><li>The company this morning <a href=\"https://seekingalpha.com/pr/16966433-genesis-energy-l-p-confirms-previous-financial-guidance-plans-enhance-balance-sheet-financial\" target=\"_blank\">slashed its dividend </a>to $0.50 per unit from $0.73. Beginning at the start of next year, the hope is to grow the payout by no less than $0.01 per unit per quarter.</li><li>The targeted distribution coverage will be 1.4x-1.6x, and leverage is hoped to be cut to 4.75x, 4.25x, and 3.75x by the ends of 2018, 19, and 20, respectively.</li><li><a href='https://seekingalpha.com/symbol/GEL' title='Genesis Energy, L.P.'>GEL</a> was down as much as 9%, but has&nbsp;<font color='red'>trimmed that to 3.4%</font>.</li><li>Hedgeye just hit the wires, suggesting 50% downside in the stock price.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300748\" data-linked=\"Genesis Energy down more than 3% after distribution cut\" data-tweet=\"$GEL - Genesis Energy down more than 3% after distribution cut https://seekingalpha.com/news/3300748-genesis-energy-down-3-after-distribution-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3300748-genesis-energy-down-3-after-distribution-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300747\" data-ts=\"1507831264\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300747-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CHNR' title='China Natural Resources, Inc.'>CHNR</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/NAK' title='Northern Dynasty Minerals Ltd'>NAK</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/LTBR' title='Lightbridge Corp'>LTBR</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/JONE' title='Jones Energy, Inc.'>OTC:JONE</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/HOS' title='Hornbeck Offshore Services, Inc.'>HOS</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/FET' title='Forum Energy Technologies'>FET</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/PQ' title='PetroQuest Energy Inc.'>PQ</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/MDR' title='McDermott International, Inc.'>MDR</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300747\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$CHNR $NAK $LTBR - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3300747-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3300747-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300742\" data-ts=\"1507831172\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEVA\" target=\"_blank\">TEVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300742-teva-under-pressure-down-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Teva under pressure, down 4%</a></h4><ul><li>Beleaguered Teva Pharmaceutical Industries (<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color='red'>-4.2%</font>) is down on below average volume in a retest of the recent low of $15.22 touched on September 6. Shares are currently exchanging hands at $15.05, a 52-week low.</li><li>No particular news accounts for the action. Earlier today, the company settled its patent challenge with BioDelivery Sciences related to pain med BUNAVAIL but that should not have moved the needle much.</li><li>Pharmaceuticals and biotechs are down in general.</li><li>(<a href='https://seekingalpha.com/symbol/PJP' title='Invesco Dynamic Pharmaceuticals Portfolio ETF'>PJP</a> <font color='red'>-0.9%</font>)(<a href='https://seekingalpha.com/symbol/IHE' title='iShares U.S. Pharmaceuticals ETF'>IHE</a> <font color='red'>-0.6%</font>)(<a href='https://seekingalpha.com/symbol/XPH' title='SPDR S&P Pharmaceuticals ETF'>XPH</a> <font color='red'>-0.9%</font>)(<a href='https://seekingalpha.com/symbol/IBB' title='iShares Nasdaq Biotechnology ETF'>IBB</a> <font color='red'>-0.7%</font>)(<a href='https://seekingalpha.com/symbol/XBI' title='SPDR Biotech ETF'>XBI</a> <font color='red'>-0.3%</font>)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3300616-biodelivery-sciences-settles-bunavail-patent-dispute-teva\" target=\"_blank\">BioDelivery Sciences settles Bunavail patent dispute with Teva</a> (Oct. 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3300742\" data-linked=\"Teva under pressure, down 4%\" data-tweet=\"$TEVA $TEVA $PJP - Teva under pressure, down 4% https://seekingalpha.com/news/3300742-teva-under-pressure-down-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3300742-teva-under-pressure-down-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>145&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300744\" data-ts=\"1507830296\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CARG\" target=\"_blank\">CARG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300744-cargurus-up-75-after-ipo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CarGurus up 75% after IPO</a></h4><ul><li>The online auto-shopping platform last night priced its IPO at a better-than-hoped $16 per share and is currently trading hands under the ticker <a href='https://seekingalpha.com/symbol/CARG' title='CarGurus, Inc.'>CARG</a> at $28.15.</li><li>Talking to Bloomberg, CEO Langley Steinert says some of that raised capital might be put to work in M&amp;A in what he calls a \"fragmented\" car-dealer technology space.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3300577-cargurus-prices-ipo-16-share-top-range\" target=\"_blank\">CarGurus prices IPO at $16/share, above top of range</a> (Oct. 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3300744\" data-linked=\"CarGurus up 75% after IPO\" data-tweet=\"$CARG - CarGurus up 75% after IPO https://seekingalpha.com/news/3300744-cargurus-up-75-after-ipo?source=tweet\" data-url=\"https://seekingalpha.com/news/3300744-cargurus-up-75-after-ipo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300743\" data-ts=\"1507830085\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/T\" target=\"_blank\">T</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300743-t-closing-el-paso-call-center-union-seizes-on-move-amid-dispute\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AT&amp;T closing El Paso call center; union seizes on move amid dispute</a></h4><ul>   <li>AT&amp;T (NYSE:<a href='https://seekingalpha.com/symbol/T' title='AT&T Inc.'>T</a>) is <a href=\"http://www.fiercewireless.com/wireless/at-t-to-shutter-texas-call-center-as-cwa-talks-drag\" target=\"_blank\">closing its call center</a> in El Paso, Texas -- a shutdown that the Communications Workers of America is publicizing with the claim that it shows eagerness to offshore jobs.</li>    <li>The company says all affected employees are being offered positions in other AT&amp;T offices.</li>    <li>The two sides are in a ninth month of talks over a dispute that covers about 20,000 AT&amp;T Mobility employees in 36 states (about 7% of the total workforce). Almost 40,000 workers went on strike for three days in May.</li>    <li>The company used to operate three call centers in El Paso; CWA says AT&amp;T has eliminated 12,000 call center jobs nationwide since 2011.</li>    <li>Shares are <font color='red'>4.3% lower</font> today after an <a href=\"https://seekingalpha.com/news/3300564-t-filing-natural-disasters-hitting-earnings-directv-now-300k-adds\" target=\"_blank\">SEC filing yesterday</a> shows that while streaming service DirecTV Now is adding subscribers, AT&amp;T's linear TV subscribers are down by about 390,000 this quarter.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300743\" data-linked=\"AT&amp;T closing El Paso call center; union seizes on move amid dispute\" data-tweet=\"$T - AT&amp;T closing El Paso call center; union seizes on move amid dispute https://seekingalpha.com/news/3300743-t-closing-el-paso-call-center-union-seizes-on-move-amid-dispute?source=tweet\" data-url=\"https://seekingalpha.com/news/3300743-t-closing-el-paso-call-center-union-seizes-on-move-amid-dispute\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300740\" data-ts=\"1507829645\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300740-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CCCR-OLD' title='China Commercial Credit'>CCCR-OLD</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/PMTS' title='CPI Card Group'>PMTS</a> <font color='green'>+11%</font>.<a href='https://seekingalpha.com/symbol/NMIH' title='NMI Holdings, Inc.'>NMIH</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/HAWK' title='Blackhawk Network Holdings, Inc.'>HAWK</a> <font color='red'>-19%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300740\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$CCCR-OLD $PMTS $NMIH - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3300740-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3300740-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300738\" data-ts=\"1507828380\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DXC\" target=\"_blank\">DXC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300738-dxc-technologyplus-4-on-plan-to-spin-off-u-s-public-sector-business\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DXC Technology +4% on plan to spin off U.S. public sector business</a></h4><ul>     <li>DXC Technology (<a href='https://seekingalpha.com/symbol/DXC' title='DXC Technology'>DXC</a> <font color='green'>+4%</font>) is higher after unveiling plans to <a href=\"https://seekingalpha.com/pr/16966247-dxc-technology-combine-u-s-public-sector-business-vencore-holding-corporation-keypoint\" target=\"_blank\">merge its U.S. Public Sector business</a> with two Veritas Capital affiliates to form an independent publicly traded company serving U.S. government clients.</li>     <li>DXC says its combination with Vencore Holding and KeyPoint Government Solutions will create a top-five services provider to the U.S. government.</li>     <li>Barclays raises its DXC price target to $100 from $90 on the news, noting that the Reverse Morris Trust structure will allow the proposed combination to qualify as a tax-free transaction for DXC shareholders; the firm also sees a high probability of obtaining regulatory approvals.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300738\" data-linked=\"DXC Technology +4% on plan to spin off U.S. public sector business\" data-tweet=\"$DXC - DXC Technology +4% on plan to spin off U.S. public sector business https://seekingalpha.com/news/3300738-dxc-technologyplus-4-on-plan-to-spin-off-u-s-public-sector-business?source=tweet\" data-url=\"https://seekingalpha.com/news/3300738-dxc-technologyplus-4-on-plan-to-spin-off-u-s-public-sector-business\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300737\" data-ts=\"1507828169\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ONCE\" target=\"_blank\">ONCE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300737-prospects-bullish-for-positive-ad-com-vote-for-sparks-gene-therapy-luxturna\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Prospects bullish for positive Ad Com vote for Spark&#39;s gene therapy Luxturna</a></h4><ul><li>The FDA's Cellular, Tissue and Gene Therapies Advisory Committee will vote in a short while on Spark Therapeutics' (<a href='https://seekingalpha.com/symbol/ONCE' title='Spark Therapeutics'>ONCE</a>) marketing application for gene therapy LUXTURNA (voretigene neparvovec) for the treatment of RPE65 mutation-associated retinal dystrophy.</li><li>The patient testimonials were especially moving. It looks good for a thumbs up.</li><li>Trading, suspended since before 7:00 am ET this morning, should resume after the vote.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300737\" data-linked=\"Prospects bullish for positive Ad Com vote for Spark&#39;s gene therapy Luxturna\" data-tweet=\"$ONCE - Prospects bullish for positive Ad Com vote for Spark&#39;s gene therapy Luxturna https://seekingalpha.com/news/3300737-prospects-bullish-for-positive-ad-com-vote-for-sparks-gene-therapy-luxturna?source=tweet\" data-url=\"https://seekingalpha.com/news/3300737-prospects-bullish-for-positive-ad-com-vote-for-sparks-gene-therapy-luxturna\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:09 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300735\" data-ts=\"1507827435\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/POLA\" target=\"_blank\">POLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300735-polar-powerplus-13-on-dc-power-systems-order-for-puerto-rico\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Polar Power +13% on DC power systems order for Puerto Rico</a></h4><ul>     <li>Polar Power (<a href='https://seekingalpha.com/symbol/POLA' title='Polar Power Inc'>POLA</a> <font color='green'>+13%</font>) pushes higher following news that it received a <a href=\"https://seekingalpha.com/pr/16966772-polar-power-receives-multi-unit-purchase-order-dc-power-systems-new-tierminus-1-wireless\" target=\"_blank\">multi-unit purchase order</a> of its 15 KW back-up diesel direct current generator set from a new Tier-1 wireless carrier for the Puerto Rico market.</li>     <li>POLA says an initial 57 units will be shipped over the next two weeks to hurricane-affected telecom sites on the island of Puerto Rico.</li>     <li>POLA says ~75% of fiber coverage, including cellular service, and 40% of the island's wired network, still is not working.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300735\" data-linked=\"Polar Power +13% on DC power systems order for Puerto Rico\" data-tweet=\"$POLA - Polar Power +13% on DC power systems order for Puerto Rico https://seekingalpha.com/news/3300735-polar-powerplus-13-on-dc-power-systems-order-for-puerto-rico?source=tweet\" data-url=\"https://seekingalpha.com/news/3300735-polar-powerplus-13-on-dc-power-systems-order-for-puerto-rico\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300734\" data-ts=\"1507826891\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300734-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/INFI' title='Infinity Pharmaceuticals, Inc.'>INFI</a> <font color='green'>+81%</font>. <a href='https://seekingalpha.com/symbol/ARDX' title='Ardelyx'>ARDX</a> <font color='green'>+52%</font>. <a href='https://seekingalpha.com/symbol/CCCL' title='China Ceramics Co., Ltd.'>CCCL</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/CCCR-OLD' title='China Commercial Credit'>CCCR-OLD</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/ONCS' title='OncoSec Medical Incorporated'>ONCS</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/ISDR' title='Issuer Direct Corp.'>ISDR</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/ZFGN' title='Zafgen, Inc.'>ZFGN</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/POLA' title='Polar Power Inc'>POLA</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/BLIN' title='Bridgeline Digital, Inc.'>BLIN</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/SPAR' title='Spartan Motors, Inc.'>SPAR</a> <font color='green'>+12%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ACRX' title='AcelRx Pharmaceuticals, Inc.'>ACRX</a> <font color='red'>-57%</font>. <a href='https://seekingalpha.com/symbol/JILL' title='J. Jill Group, Inc.'>JILL</a> <font color='red'>-50%</font>. <a href='https://seekingalpha.com/symbol/NSTG' title='NanoString Technologies'>NSTG</a> <font color='red'>-33%</font>. <a href='https://seekingalpha.com/symbol/ORPN' title='Bio Blast Pharma'>ORPN</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/HAWK' title='Blackhawk Network Holdings, Inc.'>HAWK</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/TRVN' title='Trevena, Inc.'>TRVN</a> <font color='red'>-16%</font>. WPCS <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/LBIX-OLD' title='Leading Brands Inc'>LBIX-OLD</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/PTGX' title='Protagonist Therapeutics'>PTGX</a> <font color='red'>-14%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300734\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$INFI $ARDX $CCCL - Midday Gainers / Losers https://seekingalpha.com/news/3300734-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3300734-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300731\" data-ts=\"1507826551\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EFX\" target=\"_blank\">EFX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300731-equifaxminus-2_8-investigating-another-possible-data-breach\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Equifax -2.8%, investigating another possible data breach</a></h4><ul>   <li>Equifax (NYSE:<a href='https://seekingalpha.com/symbol/EFX' title='Equifax Inc.'>EFX</a>) data may have been <a href=\"https://www.cnbc.com/2017/10/12/equifax-says-it-might-have-been-breached-again.html\" target=\"_blank\">breached again</a>, as the company has taken a Web page offline and says its security team is looking into reports of another hack.</li>    <li>Shares are <font color='red'>-2.8%</font> to session lows; shares are at their lowest point this month.</li>    <li>An independent security analyst yesterday found Equifax's website <a href=\"https://arstechnica.com/information-technology/2017/10/equifax-website-hacked-again-this-time-to-redirect-to-fake-flash-update/\" target=\"_blank\">under control of attackers</a> attempting to get malware onto visitors' computers via fraudulent Adobe Flash updates.</li>    <li>The company's fresh off news that <a href=\"https://seekingalpha.com/news/3300250-equifax-hack-included-breach-drivers-license-data-wsj\" target=\"_blank\">driver's license data</a> on 10.9M Americans were compromised in the cyber attack that exposed the personal information of more than 140M Americans.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300731\" data-linked=\"Equifax -2.8%, investigating another possible data breach\" data-tweet=\"$EFX - Equifax -2.8%, investigating another possible data breach https://seekingalpha.com/news/3300731-equifaxminus-2_8-investigating-another-possible-data-breach?source=tweet\" data-url=\"https://seekingalpha.com/news/3300731-equifaxminus-2_8-investigating-another-possible-data-breach\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>41&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300728\" data-ts=\"1507825370\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRTO\" target=\"_blank\">CRTO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300728-criteo-shares-fall-after-accusation-of-illegal-and-harmful-practices\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Criteo shares fall after accusation of &quot;illegal and harmful&quot; practices</a></h4><ul><li>        Criteo (NASDAQ:<a href='https://seekingalpha.com/symbol/CRTO' title='Criteo S.A.'>CRTO</a>) shares are<font color='red'> down 1.27%</font>&nbsp;after a <a href=\"https://gothamcityresearch.com/2017/10/12/criteo-sa-nasdaq-crto-why-we-believe-criteos-undisclosed-practices-are-illegal-and-harmful-to-advertisers/\" target=\"_blank\">Gotham City Research report</a> accused the company of &ldquo;illegal and harmful&rdquo; practices.</li><li>               Gotham City cites Criteo&rsquo;s workaround for Apple&rsquo;s Intelligent Tracking Prevention feature and says that either the FTC, Apple, or investor pressure will force Criteo to stop.&nbsp;</li><li>               The report also says Criteo&rsquo;s practices will violate new European regulations coming in May. &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3296750-criteo-minus-1_6-percent-late-trade-ahead-gotham-city-short-report\" target=\"_blank\">Criteo -1.6% in late trade ahead of Gotham City short report</a> (Sept. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3300728\" data-linked=\"Criteo shares fall after accusation of &quot;illegal and harmful&quot; practices\" data-tweet=\"$CRTO - Criteo shares fall after accusation of &quot;illegal and harmful&quot; practices https://seekingalpha.com/news/3300728-criteo-shares-fall-after-accusation-of-illegal-and-harmful-practices?source=tweet\" data-url=\"https://seekingalpha.com/news/3300728-criteo-shares-fall-after-accusation-of-illegal-and-harmful-practices\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:22 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300727\" data-ts=\"1507825285\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HA\" target=\"_blank\">HA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300727-hawaiian-holdings-drops-after-southwest-says-aloha\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hawaiian Holdings drops after Southwest says aloha</a></h4><ul> <li>Hawaiian Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/HA' title='Hawaiian Holdings, Inc.'>HA</a>) is <font color='red'>down 2.30%</font> after Southwest Airlines (<a href='https://seekingalpha.com/symbol/LUV' title='Southwest Airlines Co.'>LUV</a> <font color='green'>+1.2%</font>) launches service to Hawaii.</li> <li>Southwest ticket sales are <a href=\"http://www.hawaiinewsnow.com/story/36577141/low-cost-carrier-southwest-to-launch-service-to-hawaii\" target=\"_blank\">expected</a> to begin next year. The carrier is currently working on landing FAA approvals for the route to the Hawaiian islands.</li> <li>Seeking Alpha contributor Aparecium Research was out a few weeks ago with an <a href=\"https://seekingalpha.com/article/4107459-crash-ahead-hawaiian-airlines-stock-southwest-market-entry-may-imminent\" target=\"_blank\">article</a> warning on the potential for Southwest to make the move.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300727\" data-linked=\"Hawaiian Holdings drops after Southwest says aloha\" data-tweet=\"$HA $HA $LUV - Hawaiian Holdings drops after Southwest says aloha https://seekingalpha.com/news/3300727-hawaiian-holdings-drops-after-southwest-says-aloha?source=tweet\" data-url=\"https://seekingalpha.com/news/3300727-hawaiian-holdings-drops-after-southwest-says-aloha\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300724\" data-ts=\"1507824068\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300724-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SPAR' title='Spartan Motors, Inc.'>SPAR</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/FFHL' title='Fuwei Films &#40;Holdings&#41; Co., Ltd.'>FFHL</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/MERC' title='Mercer International Inc.'>MERC</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/LBIX-OLD' title='Leading Brands Inc'>LBIX-OLD</a> <font color='red'>-18%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300724\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$SPAR $FFHL $MERC - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3300724-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3300724-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300717\" data-ts=\"1507822935\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JNPR\" target=\"_blank\">JNPR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300717-juniper-networksminus-5_7-on-bad-prelims-mkm-calls-sector-peers-immune\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Juniper Networks -5.7% on bad prelims, but MKM calls sector peers immune</a></h4><ul>   <li>Juniper Networks (NYSE:<a href='https://seekingalpha.com/symbol/JNPR' title='Juniper Networks'>JNPR</a>) has followed up postmarket declines yesterday with a <font color='red'>5.7% drop</font> today after the company noted <a href=\"https://seekingalpha.com/news/3300525-juniper-networks-minus-4_1-percent-preliminary-q3-numbers-fall-short\" target=\"_blank\">preliminary Q3 results</a> are being hurt by a disappointing cloud vertical.</li>    <li>Also lower today are peers Nokia (<a href=\"http://seekingalpha.com/symbol/NOK\" target=\"_blank\">NOK</a> <font color='red'>-1%</font>) and Cisco Systems (<a href=\"http://seekingalpha.com/symbol/CSCO\" target=\"_blank\">CSCO</a> <font color='red'>-0.5%</font>), though MKM Partners thinks Juniper's announcement \"looks company specific\" and Natixis says that Nokia and Ericsson (NASDAQ:<a href='https://seekingalpha.com/symbol/ERIC' title='LM Ericsson Telephone Company'>ERIC</a>) won't see negative impact from Juniper results.</li>    <li>Cisco's quarter is trending positively despite facing some of the same issues as Juniper -- including virtualization of routers, cloud competition and reliance on expensive proprietary silicon, MKM's Michael Genovese says. (h/t Bloomberg)</li>    <li>Competition from Arista Networks (<a href=\"http://seekingalpha.com/symbol/ANET\" target=\"_blank\">ANET</a> <font color='red'>-0.8%</font>) is a Juniper headwind; MKM is expecting an earnings beat/raise from Arista and a miss from F5 Networks (<a href=\"http://seekingalpha.com/symbol/FFIV\" target=\"_blank\">FFIV</a> <font color='green'>+0.2%</font>).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300717\" data-linked=\"Juniper Networks -5.7% on bad prelims, but MKM calls sector peers immune\" data-tweet=\"$JNPR $JNPR $ERIC - Juniper Networks -5.7% on bad prelims, but MKM calls sector peers immune https://seekingalpha.com/news/3300717-juniper-networksminus-5_7-on-bad-prelims-mkm-calls-sector-peers-immune?source=tweet\" data-url=\"https://seekingalpha.com/news/3300717-juniper-networksminus-5_7-on-bad-prelims-mkm-calls-sector-peers-immune\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3328923\" data-ts=\"1507822841\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3328923-eia-petroleum-inventories\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EIA Petroleum Inventories</a></h4><ul>     <li><a href=\"http://ir.eia.gov/wpsr/wpsrsummary.pdf\" target=\"_blank\">EIA Petroleum Inventories:</a> Crude <strong>+1.9</strong><strong>M</strong> barrels vs. +3.2M consensus, +6.8M last week.</li><li>Gasoline <strong>+3.4M</strong> barrels vs. +0.5M consensus, -2.0M last week.</li><li>Distillates <strong>+3.9</strong><strong>M </strong>barrels vs. -1.4M consensus, -1.9M last week.</li><li>Futures&nbsp;<font color='red'>-1.81%</font>&nbsp;to $62.24.</li><li>ETFs:<a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Ultra Bloomberg Crude Oil ETF'>UCO</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/DBO' title='PowerShares DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/USL' title='The United States 12 Month Oil ETF, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/DNO' title='The United States Short Oil ETF, LP'>DNO</a>, <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3328923\" data-linked=\"EIA Petroleum Inventories\" data-tweet=\"$USO $OIL $UCO - EIA Petroleum Inventories https://seekingalpha.com/news/3328923-eia-petroleum-inventories?source=tweet\" data-url=\"https://seekingalpha.com/news/3328923-eia-petroleum-inventories\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300714\" data-ts=\"1507822244\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPI\" target=\"_blank\">SPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300714-spi-energyplus-36-on-share-purchase-deals\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SPI Energy +36% on share purchase deals</a></h4><ul>     <li>Solar equipment provider SPI Energy (<a href='https://seekingalpha.com/symbol/SPI' title='SPI Energy Co., Ltd.'>SPI</a> <font color='green'>+36.1%</font>) skyrockets on news that two Chinese investment funds <a href=\"https://seekingalpha.com/pr/16966563-spi-energy-co-ltd-announces-private-placements\" target=\"_blank\">agreed to purchase</a> nearly $34M worth of shares in the company.</li><li>SPI says Qian Kun Prosperous Times Investment and Alpha Assai fund SP of Sunrise SPC will purchase a respective 80M and 240M shares of the company.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300714\" data-linked=\"SPI Energy +36% on share purchase deals\" data-tweet=\"$SPI - SPI Energy +36% on share purchase deals https://seekingalpha.com/news/3300714-spi-energyplus-36-on-share-purchase-deals?source=tweet\" data-url=\"https://seekingalpha.com/news/3300714-spi-energyplus-36-on-share-purchase-deals\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300712\" data-ts=\"1507821794\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UNP\" target=\"_blank\">UNP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300712-jpmorgan-weighs-in-on-union-pacific-ahead-of-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JPMorgan weighs in on Union Pacific ahead of earnings</a></h4><ul> <li>JPMorgan <a href=\"https://www.streetinsider.com/Analyst+Comments/Union+Pacific+%28UNP%29+PT+Raised+to+%24113+at+JPMorgan+on+3Q+Earnings+Preview%3B+Ongoing+Progress+Regarding+Productivity+Initiatives/13383835.html\" target=\"_blank\">hikes</a> its price target on Union Pacific (<a href='https://seekingalpha.com/symbol/UNP' title='Union Pacific Corporation'>UNP</a> <font color='green'>+0.5%</font>) to $113 on a positive view of how Q3 earnings will shake out.</li> <li>Union Pacific is due to report earnings on October 26.</li> <li>Shares of Union Pacific are up about 4% since the last time the railroad operators spilled quarterly numbers.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300712\" data-linked=\"JPMorgan weighs in on Union Pacific ahead of earnings\" data-tweet=\"$UNP - JPMorgan weighs in on Union Pacific ahead of earnings https://seekingalpha.com/news/3300712-jpmorgan-weighs-in-on-union-pacific-ahead-of-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3300712-jpmorgan-weighs-in-on-union-pacific-ahead-of-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300709\" data-ts=\"1507821332\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPAR\" target=\"_blank\">SPAR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300709-spartan-motors-soars-on-aggressive-growth-talk\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Spartan Motors soars on aggressive growth talk</a></h4><ul>     <li>Spartan Motors (<a href='https://seekingalpha.com/symbol/SPAR' title='Spartan Motors, Inc.'>SPAR</a> <font color='green'>+12.8%</font>) rallies after updating investors at its analyst day event/</li>     <li>\"Through improved operational discipline and performance, increased accountability and an acute focus on strengthening our team, we are accelerating growth,\" says CEO Daryl Adams</li>     <li>\"We saw the potential to nearly double revenues and have set an aspirational, yet achievable goal with our long-term growth strategy,\" adds Adams.</li>         <li>Spartan's goals include become the #1 or #2 player in each market it serves, as well as $1B in sales by 2020.</li>  <li>Source: <a href=\"https://seekingalpha.com/pr/16966930-spartan-motors-unveil-long-term-growth-plan-analyst-investor-day-showcase-16-vehicles\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3300709\" data-linked=\"Spartan Motors soars on aggressive growth talk\" data-tweet=\"$SPAR - Spartan Motors soars on aggressive growth talk https://seekingalpha.com/news/3300709-spartan-motors-soars-on-aggressive-growth-talk?source=tweet\" data-url=\"https://seekingalpha.com/news/3300709-spartan-motors-soars-on-aggressive-growth-talk\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300705\" data-ts=\"1507820619\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WYNN\" target=\"_blank\">WYNN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300705-edgy-trading-on-casino-stocks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Edgy trading on casino stocks</a></h4><ul> <li>There's a bit of a risk-on trade in the casino sector as some estimates in Macau are cut after a softish Golden Week in Macau and a lawsuit against MGM tied to the Las Vegas mass shooting garners attention.</li> <li>Wynn Resorts (<a href='https://seekingalpha.com/symbol/WYNN' title='Wynn Resorts, Limited'>WYNN</a> <font color='red'>-1.9%</font>), MGM Resorts (<a href='https://seekingalpha.com/symbol/MGM' title='MGM Resorts International'>MGM</a> <font color='red'>-2%</font>), Las Vegas Sands (<a href='https://seekingalpha.com/symbol/LVS' title='Las Vegas Sands Corp.'>LVS</a> <font color='red'>-2.3%</font>), Melco Resorts &amp; Entertainment (<a href='https://seekingalpha.com/symbol/MLCO' title='Melco Resorts & Entertainment Limited ADR'>MLCO</a> <font color='red'>-1.3%</font>), Red Rock Resorts (<a href='https://seekingalpha.com/symbol/RRR' title='Red Rock Resorts'>RRR</a> <font color='red'>-0.9%</font>) and Boyd Gaming (<a href='https://seekingalpha.com/symbol/BYD' title='Boyd Gaming Corporation'>BYD</a> <font color='red'>-0.8%</font>) are some of the names seeing extra volatility.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3300705\" data-linked=\"Edgy trading on casino stocks\" data-tweet=\"$WYNN $WYNN $MGM - Edgy trading on casino stocks https://seekingalpha.com/news/3300705-edgy-trading-on-casino-stocks?source=tweet\" data-url=\"https://seekingalpha.com/news/3300705-edgy-trading-on-casino-stocks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300704\" data-ts=\"1507820580\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SIGM\" target=\"_blank\">SIGM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300704-sigma-designs-announces-restructuring-plan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sigma Designs announces restructuring plan</a></h4><ul><li>        Sigma Designs (NASDAQ:<a href='https://seekingalpha.com/symbol/SIGM' title='Sigma Designs, Inc.'>SIGM</a>) <a href=\"https://seekingalpha.com/pr/16966147-sigma-designs-inc-announces-major-restructuring-actions-accelerate-return-profitability\" target=\"_blank\">announces</a> restructuring activities to streamline the Connected Smart TV Platforms business and accelerate a return to profitability.</li><li>               Sigma expects the restructuring to complete by the end of Q4 FY18 and plans to cut 200 to 250 jobs in that time.&nbsp;</li><li>                  Sigma estimates non-GAAP operating expenses to drop from $26M in Q2 FY18 to between $17M and $18M in early FY19. One-time charges will total $8M to $10M over Q3 and Q4. Other charges will total between $5M and $7M.    </li><li>               Sigma Designs shares are&nbsp;<font color='red'>down 2.67%</font>.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3300704\" data-linked=\"Sigma Designs announces restructuring plan\" data-tweet=\"$SIGM - Sigma Designs announces restructuring plan https://seekingalpha.com/news/3300704-sigma-designs-announces-restructuring-plan?source=tweet\" data-url=\"https://seekingalpha.com/news/3300704-sigma-designs-announces-restructuring-plan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300676\" data-ts=\"1507820457\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300676-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/INFI' title='Infinity Pharmaceuticals, Inc.'>INFI</a> <font color='green'>+67%</font>. <a href='https://seekingalpha.com/symbol/ARDX' title='Ardelyx'>ARDX</a> <font color='green'>+45%</font>. <a href='https://seekingalpha.com/symbol/ONCS' title='OncoSec Medical Incorporated'>ONCS</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/ZFGN' title='Zafgen, Inc.'>ZFGN</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/AEZS' title='AEterna Zentaris, Inc.'>AEZS</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ACRX' title='AcelRx Pharmaceuticals, Inc.'>ACRX</a> <font color='red'>-57%</font>. <a href='https://seekingalpha.com/symbol/NSTG' title='NanoString Technologies'>NSTG</a> <font color='red'>-36%</font>. <a href='https://seekingalpha.com/symbol/TRVN' title='Trevena, Inc.'>TRVN</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/ORPN' title='Bio Blast Pharma'>ORPN</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/PTGX' title='Protagonist Therapeutics'>PTGX</a> <font color='red'>-12%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300676\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$INFI $ARDX $ONCS - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3300676-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3300676-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300703\" data-ts=\"1507820441\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300703-crude-futures-pares-losses-post-inventory-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crude futures pares losses post inventory data</a></h4><ul>     <li><a href=\"http://ir.eia.gov/wpsr/wpsrsummary.pdf\" target=\"_blank\">EIA Petroleum Inventories:</a> Crude <strong>-2.8M</strong> barrels vs. -2.0M consensus, -6.0M last week.</li><li>Gasoline <strong>+2.5M</strong> barrels vs. -0.5M consensus, +1.6M last week.</li><li>Distillates <strong>-1.5M </strong>barrels vs. -2.2M consensus, -2.6M last week.</li><li>Futures&nbsp;<font color='red'>-2.01%</font>&nbsp;to $50.27.</li><li>ETFs:<a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Ultra Bloomberg Crude Oil ETF'>UCO</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/DBO' title='PowerShares DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/USL' title='The United States 12 Month Oil ETF, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/DNO' title='The United States Short Oil ETF, LP'>DNO</a>, <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3300703\" data-linked=\"Crude futures pares losses post inventory data\" data-tweet=\"$USO $OIL $UCO - Crude futures pares losses post inventory data https://seekingalpha.com/news/3300703-crude-futures-pares-losses-post-inventory-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3300703-crude-futures-pares-losses-post-inventory-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>52&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300701\" data-ts=\"1507820290\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TREE\" target=\"_blank\">TREE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300701-lendingtree-down-2_3-bull-turns-to-bear\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LendingTree down 2.3% as bull turns to bear</a></h4><ul><li>Nearly a three-bagger over the past 12 months, LendingTree (NASDAQ:<a href='https://seekingalpha.com/symbol/TREE' title='LendingTree, Inc.'>TREE</a>) is now \"priced for perfection,\" says BWS Financial's&nbsp;Hamed Khorsand. Seasonal factors in Q4 could be the catalyst for a \"snap back,\" he says.</li><li>He downgrades from Buy to Sell, and cuts his price target to $194 from $285.</li><li>Shares&nbsp;<font color='red'>down 2.3%</font>&nbsp;to $251.75.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300701\" data-linked=\"LendingTree down 2.3% as bull turns to bear\" data-tweet=\"$TREE - LendingTree down 2.3% as bull turns to bear https://seekingalpha.com/news/3300701-lendingtree-down-2_3-bull-turns-to-bear?source=tweet\" data-url=\"https://seekingalpha.com/news/3300701-lendingtree-down-2_3-bull-turns-to-bear\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300699\" data-ts=\"1507819568\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMPE\" target=\"_blank\">AMPE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300699-combined-analysis-of-completed-studies-of-ampios-ampion-in-oak-to-be-published-in-orthopedics\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Combined analysis of completed studies of Ampio&#39;s Ampion in OAK to be published in Orthopedics journal; shares up 3%</a></h4><ul><li>Nano cap Ampio Pharmaceuticals (<a href='https://seekingalpha.com/symbol/AMPE' title='Ampio Pharmaceuticals, Inc.'>AMPE</a> <font color='green'>+3%</font>) is up on lower-than-average volume in apparent reaction to its <a href=\"https://seekingalpha.com/pr/16966735-ampio-announces-accepted-publication-pooled-ampion-clinical-trial-results-patients-severe\" target=\"_blank\">announcement </a>that a combined analysis from 417 patients across all completed studies assessing a single intra-articular injection of Ampion in patients with severe osteoarthritis of the knee &#40;OAK&#41; has been accepted for publication in the journal <em>Orthopedics</em>.</li><li>The company says the analysis showed Ampion not only to be safe and well-tolerated, but patients receiving an injection into the knee joint were more likely to respond to treatment with a longer duration of response compared to saline.</li><li><a href=\"http://ampiopharma.com/pipeline/ampion/\" target=\"_blank\">Ampion&nbsp;</a>is a low molecular weight fraction of human serum albumin &#40;HSA&#41;. Its main ingredient is an immunomodulatory molecule derived from HSA called aspartyl-alanyl diketopiperazine (DA-DKP), believed to reduce inflammation by suppressing pro-inflammatory cytokine production in T cells.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300699\" data-linked=\"Combined analysis of completed studies of Ampio&#39;s Ampion in OAK to be published in Orthopedics journal; shares up 3%\" data-tweet=\"$AMPE - Combined analysis of completed studies of Ampio&#39;s Ampion in OAK to be published in Orthopedics journal; shares up 3% https://seekingalpha.com/news/3300699-combined-analysis-of-completed-studies-of-ampios-ampion-in-oak-to-be-published-in-orthopedics?source=tweet\" data-url=\"https://seekingalpha.com/news/3300699-combined-analysis-of-completed-studies-of-ampios-ampion-in-oak-to-be-published-in-orthopedics\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300693\" data-ts=\"1507818612\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300693-eia-natural-gas-inventory\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EIA Natural Gas Inventory</a></h4><ul>     <li><a href=\"http://ir.eia.gov/ngs/ngs.html\" target=\"_blank\">EIA Natural Gas Inventory:</a> <strong>+87 Bcf</strong> vs. +82 Bcf consensus, +42 Bcf last week.</li><li>Futures&nbsp;<font color='green'>+2.22%</font>&nbsp;to $2.953.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a>, <a href='https://seekingalpha.com/symbol/DGAZ' title='VelocityShares 3x Inverse Natural Gas ETN'>DGAZ</a>, <a href='https://seekingalpha.com/symbol/UGAZ' title='VelocityShares 3x Long Natural Gas ETN'>UGAZ</a>, <a href='https://seekingalpha.com/symbol/BOIL' title='ProShares Ultra Bloomberg Natural Gas ETF'>BOIL</a>, <a href='https://seekingalpha.com/symbol/GAZ' title='iPath DJ-UBS Natural Gas Total Return Sub-Index ETN'>GAZ</a>, <a href='https://seekingalpha.com/symbol/KOLD' title='ProShares UltraShort Bloomberg Natural Gas ETF'>KOLD</a>, <a href='https://seekingalpha.com/symbol/UNL' title='The United States 12 Month Natural Gas ETF, LP'>UNL</a>,<a href='https://seekingalpha.com/symbol/DCNG' title='iPath Pure Beta Seasonal Natural Gas ETN'>DCNG</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300693\" data-linked=\"EIA Natural Gas Inventory\" data-tweet=\"$UNG $DGAZ $UGAZ - EIA Natural Gas Inventory https://seekingalpha.com/news/3300693-eia-natural-gas-inventory?source=tweet\" data-url=\"https://seekingalpha.com/news/3300693-eia-natural-gas-inventory\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>62&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300692\" data-ts=\"1507818504\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LNN\" target=\"_blank\">LNN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300692-lindsayminus-5-after-missing-on-earnings-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lindsay -5% after missing on earnings, revenue</a></h4><ul>     <li>Lindsay (<a href='https://seekingalpha.com/symbol/LNN' title='Lindsay Corporation'>LNN</a> <font color='red'>-5.5%</font>) is lower after reporting disappointing <a href=\"https://seekingalpha.com/news/3300596-lindsay-misses-0_05-misses-revenue\" target=\"_blank\">FQ4 earnings</a> and revenues, with the company saying it expects modest growth in its U.S. irrigation business in the upcoming year.</li>     <li>LNN says commodity prices have stabilized but are expected to remain under pressure as generally favorable weather conditions during the 2017 growing season likely will result in above average crop production levels and ending stocks.</li>     <li>FQ4 gross margin was 28.6% of sales compared to 30.1% in the prior-year quarter, with slightly lower margins in both the irrigation and infrastructure segments.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300692\" data-linked=\"Lindsay -5% after missing on earnings, revenue\" data-tweet=\"$LNN - Lindsay -5% after missing on earnings, revenue https://seekingalpha.com/news/3300692-lindsayminus-5-after-missing-on-earnings-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3300692-lindsayminus-5-after-missing-on-earnings-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300688\" data-ts=\"1507817725\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STDY\" target=\"_blank\">STDY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300688-steadymed-nabs-european-patent-protecting-infusion-site-pain-reduction-aspect-of-patchpump\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SteadyMed nabs European patent protecting infusion-site pain reduction aspect of PatchPump; shares up 3%</a></h4><ul><li>The European Patent Office <a href=\"https://seekingalpha.com/pr/16966763-steadymed-receives-notice-allowance-european-patent-relating-enhanced-reduction-infusion-site\" target=\"_blank\">issues</a> a Notice of Allowance to SteadyMed (<a href='https://seekingalpha.com/symbol/STDY' title='SteadyMed'>STDY</a> <font color='green'>+3.1%</font>) related to claims of infusion-site pain reduction via the delivery of a topical anaesthetic through the underside of its <a href=\"https://www.steadymed.com/portfolio/at-home-patient-analgesia.htm\" target=\"_blank\">PatchPump </a>infusion system for drugs administered subcutaneously.</li><li>The company's patent application was No. 13720085.3.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300688\" data-linked=\"SteadyMed nabs European patent protecting infusion-site pain reduction aspect of PatchPump; shares up 3%\" data-tweet=\"$STDY - SteadyMed nabs European patent protecting infusion-site pain reduction aspect of PatchPump; shares up 3% https://seekingalpha.com/news/3300688-steadymed-nabs-european-patent-protecting-infusion-site-pain-reduction-aspect-of-patchpump?source=tweet\" data-url=\"https://seekingalpha.com/news/3300688-steadymed-nabs-european-patent-protecting-infusion-site-pain-reduction-aspect-of-patchpump\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300677\" data-ts=\"1507816541\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SLNO\" target=\"_blank\">SLNO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300677-ema-advisory-group-backs-orphan-drug-tag-for-solenos-dccr-for-prader-willi-syndrome-shares-up\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EMA advisory group backs Orphan Drug tag for Soleno&#39;s DCCR for Prader-Willi syndrome; shares up 2%</a></h4><ul><li>The European Medicines Agency's Committee for Orphan Medicinal Products &#40;COMP&#41; adopts a <a href=\"https://seekingalpha.com/pr/16966673-soleno-therapeutics-receives-positive-opinion-european-orphan-committee-dccr-prader-willi\" target=\"_blank\">positive opinion</a> recommending Orphan Drug status for Soleno Therapeutics' (<a href='https://seekingalpha.com/symbol/SLNO' title='Soleno Therapeutics, Inc.'>SLNO</a> <font color='green'>+1.6%</font>) Diazoxide Choline Controlled-Release Tablet &#40;DCCR&#41; for the treatment of <a href=\"https://ghr.nlm.nih.gov/condition/prader-willi-syndrome\" target=\"_blank\">Prader-Willi syndrome</a>, an inherited disorder characterized by weak muscle tone, feeding difficulties, stunted growth and delayed development.</li><li>Among the benefits of Orphan Drug status in Europe is a 10-year period of market exclusivity for the indication, if approved.</li><li><a href=\"http://soleno.life/dccr/\" target=\"_blank\">DCCR </a>is a crystalline salt of diazoxide formulated as a controlled release once-a-day tablet. <a href=\"https://en.wikipedia.org/wiki/Diazoxide\" target=\"_blank\">Diazoxide </a>is a potassium channel activator (a vasodilator) which causes smooth muscle to relax by increasing membrane permeability to potassium ions.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300677\" data-linked=\"EMA advisory group backs Orphan Drug tag for Soleno&#39;s DCCR for Prader-Willi syndrome; shares up 2%\" data-tweet=\"$SLNO - EMA advisory group backs Orphan Drug tag for Soleno&#39;s DCCR for Prader-Willi syndrome; shares up 2% https://seekingalpha.com/news/3300677-ema-advisory-group-backs-orphan-drug-tag-for-solenos-dccr-for-prader-willi-syndrome-shares-up?source=tweet\" data-url=\"https://seekingalpha.com/news/3300677-ema-advisory-group-backs-orphan-drug-tag-for-solenos-dccr-for-prader-willi-syndrome-shares-up\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300670\" data-ts=\"1507815205\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTCT\" target=\"_blank\">PTCT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300670-ptc-therapeutics-earns-20m-milestone-from-roche-on-advancement-of-sma-candidate-rg7916-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PTC Therapeutics earns $20M milestone from Roche on advancement of SMA candidate RG7916; shares up 1%</a></h4><ul><li>PTC Therapeutics (<a href='https://seekingalpha.com/symbol/PTCT' title='PTC Therapeutics'>PTCT</a> <font color='green'>+0.6%</font>) nabs a <a href=\"https://seekingalpha.com/pr/16966627-spinal-muscular-atrophy-program-advances-pivotal-study-sma-patients\" target=\"_blank\">$20M milestone payment</a> from licensee Roche (<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding Ltd ADR'>OTCQX:RHHBY</a>) triggered by the initiation of the second (pivotal) part of a Phase 2 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02908685?cond=Spinal+Muscular+Atrophy&amp;titles=sunfish&amp;rank=1\" target=\"_blank\">SUNFISH</a>, assessing Orphan Drug-tagged RG7916 in pediatric and adult patients with Type 2/3 spinal muscular atrophy &#40;SMA&#41;.</li><li>The confirmatory segment of the study will randomize ~168 subjects over a 24-month treatment period. According to ClinicalTrials.gov, the estimated primary completion date is April 2019.</li><li>RG7916 is an orally administered survival motor neuron 2 (SMN2) splicing modifier. It works by targeting the underlying molecular deficiency of SMA by modulating SMN2 splicing to increase expression of full-length SMN2 mRNA from the SMN2 gene.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300670\" data-linked=\"PTC Therapeutics earns $20M milestone from Roche on advancement of SMA candidate RG7916; shares up 1%\" data-tweet=\"$PTCT $PTCT $RHHBY - PTC Therapeutics earns $20M milestone from Roche on advancement of SMA candidate RG7916; shares up 1% https://seekingalpha.com/news/3300670-ptc-therapeutics-earns-20m-milestone-from-roche-on-advancement-of-sma-candidate-rg7916-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3300670-ptc-therapeutics-earns-20m-milestone-from-roche-on-advancement-of-sma-candidate-rg7916-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300668\" data-ts=\"1507815006\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GLUU\" target=\"_blank\">GLUU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300668-glu-mobileplus-5_3-benchmark-boosts-to-buy-on-taylor-swift-app-optimism\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Glu Mobile +5.3% as Benchmark boosts to Buy on Taylor Swift app optimism</a></h4><ul>   <li>Glu Mobile (NASDAQ:<a href='https://seekingalpha.com/symbol/GLUU' title='Glu Mobile Inc.'>GLUU</a>) is <font color='green'>up 5.3%</font> premarket after getting a Street-high price target of $6 from Benchmark following an early look at its Taylor Swift lifestyle app.</li>    <li>The firm boosted Glu to Buy as analyst Mike Hickey points to a turnaround and cautious optimism around <a href=\"https://seekingalpha.com/pr/16965214-glu-releases-first-look-interactive-social-app-swift-life\" target=\"_blank\"><i>The Swift Life,</i></a> the company's partnership with the Grammy-winning pop star.</li>    <li>Bookings and EBITDA should exceed consensus, he notes, and the company should approach positive EBITDA in Q4 and through the coming fiscal year. (h/t Bloomberg)</li>    <li>The $6 target implies 58% upside from yesterday's close.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300668\" data-linked=\"Glu Mobile +5.3% as Benchmark boosts to Buy on Taylor Swift app optimism\" data-tweet=\"$GLUU - Glu Mobile +5.3% as Benchmark boosts to Buy on Taylor Swift app optimism https://seekingalpha.com/news/3300668-glu-mobileplus-5_3-benchmark-boosts-to-buy-on-taylor-swift-app-optimism?source=tweet\" data-url=\"https://seekingalpha.com/news/3300668-glu-mobileplus-5_3-benchmark-boosts-to-buy-on-taylor-swift-app-optimism\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300666\" data-ts=\"1507814796\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HMNY\" target=\"_blank\">HMNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300666-what-to-make-of-moviepass\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">What to make of MoviePass?</a></h4><ul>     <li>Helios and Matheson Analytics (NASDAQ:<a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a>) discloses that it holds a 53.7% pro-forma stake in MoviePass after increasing the purchase price of its investment to $28.5M.</li>     <li>The company also has an option to purchase additional stock in the subscription-based movie ticketing service for $20M in cash.</li>     <li>A risk disclosure included in Helios and Matheson's filing (<a href=\"https://seekingalpha.com/filing/3726126\" target=\"_blank\">SEC Form 8-K</a>) is something that warrants attention.</li>     <li>\"MoviePass has incurred losses since its inception and has a present need for additional funding. These factors raise substantial doubt about MoviePass&rsquo; ability to continue as a going concern. For the foreseeable future, MoviePass expects to fund its operations from additional debt or equity offerings and increased revenue from subscribers,\" reads the risk disclosure.</li>     <li>Concerns over MoviePass have hung over the movie theater sector (<a href='https://seekingalpha.com/symbol/AMC' title='AMC Entertainment Holdings, Inc'>AMC</a>, <a href='https://seekingalpha.com/symbol/RGC' title='Regal Entertainment Group'>RGC</a>, <a href='https://seekingalpha.com/symbol/MCS' title='Marcus Corporation'>MCS</a>, <a href='https://seekingalpha.com/symbol/IMAX' title='IMAX Corporation'>IMAX</a>, <a href='https://seekingalpha.com/symbol/CNK' title='Cinemark Holdings, Inc'>CNK</a>, <a href='https://seekingalpha.com/symbol/RDI' title='Reading International, Inc.'>RDI</a>) amid wide discussions over what the long-term impact will be on traffic.</li>       <li>Shares of HMNY are <font color='red'>down 10%</font> in premarket trading after rocketing up over 1000% in three months.</li>     <li>Previously: <a href=\"https://seekingalpha.com/news/3295534-moviepass-tops-400k-subscribers\" target=\"_blank\">MoviePass tops 400K subscribers</a> (Sept. 14)</li>     <li>Previously: <a href=\"https://seekingalpha.com/news/3300142-helios-and-matheson-plus-700-percent-month-called\" target=\"_blank\">Helios &amp; Matheson up +700% in a month, here's who called it</a> (Oct. 10)</li>     <li>Previously: <a href=\"https://seekingalpha.com/news/3300433-rally-continues-helios-and-matheson-analytics\" target=\"_blank\">Rally continues for Helios &amp; Matheson Analytics</a> (Oct. 11)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300666\" data-linked=\"What to make of MoviePass?\" data-tweet=\"$HMNY $HMNY $AMC - What to make of MoviePass? https://seekingalpha.com/news/3300666-what-to-make-of-moviepass?source=tweet\" data-url=\"https://seekingalpha.com/news/3300666-what-to-make-of-moviepass\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>83&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300665\" data-ts=\"1507814776\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300665-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/INFI' title='Infinity Pharmaceuticals, Inc.'>INFI</a> <font color='green'>+44%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16966573-infinity-announces-ipiminus-549-late-breaking-presentation-sitc-annual-meeting\" target=\"_blank\">new data</a> for IPI-549.</li>     <li><a href='https://seekingalpha.com/symbol/ARDX' title='Ardelyx'>ARDX</a> <font color='green'>+44%</font>&nbsp;as tenapanor <a href=\"https://seekingalpha.com/news/3300520-ardelyxs-tenapanor-successful-second-late-stage-ibs-c-study-shares-ahead-57-percent-hours\" target=\"_blank\">successful</a> in second late-stage IBS-C study.</li>     <li><a href='https://seekingalpha.com/symbol/ONCS' title='OncoSec Medical Incorporated'>ONCS</a> <font color='green'>+29%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16966650-oncosec-present-updated-clinical-immune-biomarker-data-monotherapy-combination-therapy\" target=\"_blank\">developing</a> DNA-based intratumoral cancer immunotherapies.</li>     <li><a href='https://seekingalpha.com/symbol/SMSI' title='Smith Micro Software, Inc.'>SMSI</a> <font color='green'>+27%</font>.</li>     <li>CLNT <font color='green'>+15%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3300606-cleantech-solutions-international-enters-exclusivity-agreement-3d-discovery\" target=\"_blank\">entering</a> into exclusivity agreement with 3D Discovery.</li>     <li><a href='https://seekingalpha.com/symbol/AVXL' title='Anavex Life Sciences Corp.'>AVXL</a> <font color='green'>+11%</font>&nbsp;as it <a href=\"https://seekingalpha.com/news/3300648-anavexs-alzheimers-candidate-anavex2minus-73-shows-encouraging-pharmacodynamics-mid-stage\" target=\"_blank\">shows</a> encouraging pharmacodynamics in mid-stage study</li>     <li><a href='https://seekingalpha.com/symbol/KTOV' title='Kitov Pharma Ltd.'>KTOV</a> <font color='green'>+10%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/CASI' title='CASI Pharmaceuticals'>CASI</a> <font color='green'>+11%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/LTBR' title='Lightbridge Corp'>LTBR</a> <font color='green'>+9%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16966679-lightbridge-receives-approval-key-patent-europe-innovative-fuel-design\" target=\"_blank\">receiving</a> approval for key patent in Europe for its innovative fuel design.</li>     <li>WPCS <font color='green'>+10%</font>.</li>     <li>BIOP <font color='green'>+7%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/BDSI' title='BioDelivery Sciences International, Inc.'>BDSI</a> <font color='green'>+6%</font>&nbsp;as it <a href=\"https://seekingalpha.com/news/3300616-biodelivery-sciences-settles-bunavail-patent-dispute-teva\" target=\"_blank\">settles</a> Bunavail patent dispute with Teva.</li>     <li><a href='https://seekingalpha.com/symbol/DXC' title='DXC Technology'>DXC</a> <font color='green'>+6%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/GLUU' title='Glu Mobile Inc.'>GLUU</a> <font color='green'>+5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300665\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$INFI $ARDX $ONCS - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3300665-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3300665-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300664\" data-ts=\"1507814456\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300664-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/ACRX' title='AcelRx Pharmaceuticals, Inc.'>ACRX</a>&nbsp;<font color='red'>-61%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3300602-fda-rejects-acelrx-pharmas-marketing-application-pain-med-dsuvia-shares-45-percent-premarket\" target=\"_blank\">receiving</a> complete response letter from the FDA for DSUVIA NDA.</li><li><a href='https://seekingalpha.com/symbol/JILL' title='J. Jill Group, Inc.'>JILL</a>&nbsp;<font color='red'>-48%</font>&nbsp;after two underwriters <a href=\"https://seekingalpha.com/news/3300618-j-jill-sinks-two-ipo-underwriters-downgrade\" target=\"_blank\">downgrade</a> rating.</li><li><a href='https://seekingalpha.com/symbol/TRVN' title='Trevena, Inc.'>TRVN</a>&nbsp;<font color='red'>-14%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3300595-premarket-analyst-action-healthcare\" target=\"_blank\">negative</a> analyst action.</li><li><a href='https://seekingalpha.com/symbol/PTGX' title='Protagonist Therapeutics'>PTGX</a>&nbsp;<font color='red'>-11%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3300598-protagonist-therapeutics-prices-stock-offering-17\" target=\"_blank\">pricing</a> public offering at $17.</li><li><a href='https://seekingalpha.com/symbol/HAWK' title='Blackhawk Network Holdings, Inc.'>HAWK</a>&nbsp;<font color='red'>-11%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3300513-blackhawk-network-beats-0_07-misses-revenue\" target=\"_blank\">Q3 result</a>.</li><li><a href='https://seekingalpha.com/symbol/GEL' title='Genesis Energy, L.P.'>GEL</a> <font color='red'>-9%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16966433-genesis-energy-l-p-confirms-previous-financial-guidance-plans-enhance-balance-sheet-financial\" target=\"_blank\">completing</a>&nbsp;a review of previous guidance and an&nbsp;analysis of alternative allocations of capital.</li><li><a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='red'>-8%</font>.</li><li><a href='https://seekingalpha.com/symbol/CLSN' title='Celsion Corporation'>CLSN</a> <font color='red'>-8%</font>.</li><li><a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a> <font color='red'>-6%</font>.</li><li><a href='https://seekingalpha.com/symbol/JNPR' title='Juniper Networks'>JNPR</a>&nbsp;<font color='red'>-5%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3300525-juniper-networks-minus-4_1-percent-preliminary-q3-numbers-fall-short\" target=\"_blank\">announcing</a> preliminary Q3 results.</li><li><a href='https://seekingalpha.com/symbol/DPZ' title='Domino&#39;s Pizza, Inc.'>DPZ</a>&nbsp;<font color='red'>-5%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3300612-dominos-pizza-beats-0_04-beats-revenue\" target=\"_blank\">Q3 result</a>.</li><li><a href='https://seekingalpha.com/symbol/MELI' title='MercadoLibre, Inc.'>MELI</a> <font color='red'>-6%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3300664\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$ACRX $JILL $TRVN - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3300664-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3300664-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300662\" data-ts=\"1507814068\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ONCS\" target=\"_blank\">ONCS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300662-oncosec-to-present-new-data-on-immunopulse-world-melanoma-conference-next-week-shares-up-23\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OncoSec to present new data on ImmunoPulse at World Melanoma conference next week; shares up 23% premarket</a></h4><ul><li>Thinly traded nano cap OncoSec Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/ONCS' title='OncoSec Medical Incorporated'>ONCS</a>) is up&nbsp;<font color='green'>23%</font>&nbsp;premarket on increased volume in apparent response to its <a href=\"https://seekingalpha.com/pr/16966650-oncosec-present-updated-clinical-immune-biomarker-data-monotherapy-combination-therapy\" target=\"_blank\">announcement </a>that new clinical data on ImmunoPulse IL-12 will be presented on October 19 in Brisbane, Australia at the 9th World Congress of Melanoma.</li><li>Updated results from its Phase 2 monotherapy study in patients with stage III/IV melanoma will be presented and contrasted with emerging data from the combination study with Merck's KEYTRUDA (pembrolizumab) (PISCES/KEYNOTE-695 study).</li></ul><div class=\"tiny-share-widget\" data-id=\"3300662\" data-linked=\"OncoSec to present new data on ImmunoPulse at World Melanoma conference next week; shares up 23% premarket\" data-tweet=\"$ONCS - OncoSec to present new data on ImmunoPulse at World Melanoma conference next week; shares up 23% premarket https://seekingalpha.com/news/3300662-oncosec-to-present-new-data-on-immunopulse-world-melanoma-conference-next-week-shares-up-23?source=tweet\" data-url=\"https://seekingalpha.com/news/3300662-oncosec-to-present-new-data-on-immunopulse-world-melanoma-conference-next-week-shares-up-23\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300653\" data-ts=\"1507813001\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LSCC\" target=\"_blank\">LSCC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300653-lattice-semiconductors-releases-q3-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lattice Semiconductors releases Q3 outlook</a></h4><ul><li>        Lattice Semiconductor (NASDAQ:<a href='https://seekingalpha.com/symbol/LSCC' title='Lattice Semiconductor Corporation'>LSCC</a>) releases a preliminary outlook for Q3 results.</li><li>               Revenue is expected between $91M and $93M for Q3 and $383M to $388M for the year.&nbsp;</li><li>               Growth margin expected within 2% of 56% for Q3, Q4, and FY17.&nbsp;</li><li>               Operating expenses: Q3, $45M to $47M; Q4, $43M to $45M; FY17, $182M to $186M.&nbsp;</li><li>               Lattice targets double-digit revenue growth in FY18, gross margin at mid-50%, and operating expenses at 37% to 38% of revenue.&nbsp;&nbsp;</li><li>Lattice shares are<font color='red'> down 4.33%</font>&nbsp;premarket.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3300653\" data-linked=\"Lattice Semiconductors releases Q3 outlook\" data-tweet=\"$LSCC - Lattice Semiconductors releases Q3 outlook https://seekingalpha.com/news/3300653-lattice-semiconductors-releases-q3-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3300653-lattice-semiconductors-releases-q3-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300652\" data-ts=\"1507812868\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHC\" target=\"_blank\">BHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300652-valeants-psoriasis-med-siliq-shows-long-term-treatment-effect-shares-ahead-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Valeant&#39;s psoriasis med SILIQ shows long-term treatment effect; shares ahead 1% premarket</a></h4><ul><li>Valeant Pharmaceuticals (VRX) unit Ortho Dermatologics <a href=\"https://seekingalpha.com/pr/16966620-ortho-dermatologics-announces-two-year-findings-pivotal-phase-3-study-siliq-brodalumab\" target=\"_blank\">announces </a>positive results from a Phase 3 extension study, AMAGINE-2, that showed treatment with SILIQ (brodalumab) sustained high levels of skin clearance for more than two years in patients with moderate-to-severe plaque psoriasis. The data are being presented today at the 2017 Fall Clinical Dermatology Conference in Las Vegas.</li><li>Over a two-year period, 59% of a \"sub-analysis group of patients\" maintained clear skin (PASI 100).</li><li>The FDA approved SILIQ, an IL-17 inhibitor, in February.</li><li>Shares are up&nbsp;<font color='green'>1%</font>&nbsp;premarket on light volume.</li><li>Previously: <a href=\"https://seekingalpha.com/news/1741933-positive-phase-3-results-for-brodalumab\" target=\"_blank\">Positive Phase 3 results for brodalumab</a> (May 9, 2014)</li></ul><div class=\"tiny-share-widget\" data-id=\"3300652\" data-linked=\"Valeant&#39;s psoriasis med SILIQ shows long-term treatment effect; shares ahead 1% premarket\" data-tweet=\"$BHC - Valeant&#39;s psoriasis med SILIQ shows long-term treatment effect; shares ahead 1% premarket https://seekingalpha.com/news/3300652-valeants-psoriasis-med-siliq-shows-long-term-treatment-effect-shares-ahead-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3300652-valeants-psoriasis-med-siliq-shows-long-term-treatment-effect-shares-ahead-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>136&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300650\" data-ts=\"1507812702\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ULTA\" target=\"_blank\">ULTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300650-ulta-beauty-swings-lower-after-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ulta Beauty swings lower after downgrade</a></h4><ul> <li>Shares of Ulta Beauty (NASDAQ:<a href='https://seekingalpha.com/symbol/ULTA' title='Ulta Beauty, Inc.'>ULTA</a>) trade weak in early action after Cleveland Research <a href=\"https://twitter.com/RatingsNetwork/status/918457569827610627\" target=\"_blank\">lowers</a> the retailer to a Neutral rating from Buy.</li> <li>Wall Street analyst scorecard on ULTA: 14 Buy equivalents, 12 Holds, Zero Sells.</li> <li>ULTA <font color='red'>-2.95%</font> premarket to $201.75 vs. a 52-week trading range of $204.01 to $314.86.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300650\" data-linked=\"Ulta Beauty swings lower after downgrade\" data-tweet=\"$ULTA - Ulta Beauty swings lower after downgrade https://seekingalpha.com/news/3300650-ulta-beauty-swings-lower-after-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3300650-ulta-beauty-swings-lower-after-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>39&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300648\" data-ts=\"1507811998\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVXL\" target=\"_blank\">AVXL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300648-anavexs-alzheimers-candidate-anavex2minus-73-shows-encouraging-pharmacodynamics-in-mid-stage\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Anavex&#39;s Alzheimer&#39;s candidate ANAVEX2-73 shows encouraging pharmacodynamics in mid-stage study; shares ahead 8% premarket</a></h4><ul><li>Thinly traded micro cap Anavex Life Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/AVXL' title='Anavex Life Sciences Corp.'>AVXL</a>) is up&nbsp;<font color='green'>8%</font>&nbsp;premarket on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/16966521-anavex-life-sciences-reports-pk-pd-data-phase-2a-trial-anavex-2minus-73-mild-moderate\" target=\"_blank\">announcement </a>of encouraging pharmacokinetic and pharmacodynamic data from its Phase 2a clinical trial assessing Alzheimer's disease &#40;AD&#41; candidate ANAVEX2-73.</li><li>It says the data show a clear concentration-effect relationship between ANAVEX2-73 and study measurements. Its activity appears to be enhanced by its active metabolite (ANAVEX19-144) which has a half-life almost 2x that of ANAVEX2-73.</li><li>The company will use Ariana Pharma's KEM advanced artificial intelligence technology to identify the best responders to inform on the design of its upcoming Phase 2/3 study.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3229389-anavexs-lead-product-candidate-successful-mid-stage-alzheimers-study-shares-ahead-8-percent\" target=\"_blank\">Anavex's lead product candidate successful in mid-stage Alzheimer's study; shares ahead 8% premarket</a> (Dec. 8, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3300648\" data-linked=\"Anavex&#39;s Alzheimer&#39;s candidate ANAVEX2-73 shows encouraging pharmacodynamics in mid-stage study; shares ahead 8% premarket\" data-tweet=\"$AVXL - Anavex&#39;s Alzheimer&#39;s candidate ANAVEX2-73 shows encouraging pharmacodynamics in mid-stage study; shares ahead 8% premarket https://seekingalpha.com/news/3300648-anavexs-alzheimers-candidate-anavex2minus-73-shows-encouraging-pharmacodynamics-in-mid-stage?source=tweet\" data-url=\"https://seekingalpha.com/news/3300648-anavexs-alzheimers-candidate-anavex2minus-73-shows-encouraging-pharmacodynamics-in-mid-stage\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300646\" data-ts=\"1507811629\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HMY\" target=\"_blank\">HMY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300646-harmony-gold-sees-south-africa-gold-production-up-12minus-14-q-q\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Harmony Gold sees South Africa gold production up 12%-14% Q/Q</a></h4><ul>     <li>Harmony Gold (NYSE:<a href='https://seekingalpha.com/symbol/HMY' title='Harmony Gold Mining Company Limited'>HMY</a>) <font color='green'>+2.1%</font> premarket after saying it expects FQ1 2018 gold production from its South African underground operations to come in <a href=\"http://www.foxbusiness.com/features/2017/10/12/harmony-sees-1q18-south-african-production-12-14-higher-than-4q17.html\" target=\"_blank\">12%-14% higher than Q4 2017</a>, due to higher volumes and grades recovered.</li>     <li>Gold production is 6%-8% higher than in the prior-year quarter; including Hidden Valley, total Q1 gold production is up 3%-5% Y/Y.</li>     <li>HMY says it remains on track to meet its full-year production guidance, which it had said in August was 1.1M oz. for the year ended June 30, at a cost of ~$1,180/oz.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300646\" data-linked=\"Harmony Gold sees South Africa gold production up 12%-14% Q/Q\" data-tweet=\"$HMY - Harmony Gold sees South Africa gold production up 12%-14% Q/Q https://seekingalpha.com/news/3300646-harmony-gold-sees-south-africa-gold-production-up-12minus-14-q-q?source=tweet\" data-url=\"https://seekingalpha.com/news/3300646-harmony-gold-sees-south-africa-gold-production-up-12minus-14-q-q\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300639\" data-ts=\"1507811231\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OPK\" target=\"_blank\">OPK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300639-opko-inks-deal-japan-tobacco-to-commercialize-rayaldee-in-japan-shares-up-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OPKO inks deal with Japan Tobacco to commercialize Rayaldee in Japan; shares up 1% premarket</a></h4><ul><li>OPKO Health (NYSEMKT:<a href='https://seekingalpha.com/symbol/OPK' title='OPKO Health, Inc.'>OPK</a>) unit EirGen Pharma <a href=\"https://seekingalpha.com/pr/16966669-opko-health-enters-exclusive-agreement-japan-tobacco-develop-commercialize-rayaldee-japan\" target=\"_blank\">inks an agreement </a>with Japan Tobacco granting it an exclusive license to develop and commercialize RAYALDEE (calcifediol) in Japan for the treatment of secondary hyperparathyroidism in non-dialysis and dialysis patients with chronic kidney disease &#40;CKD&#41;.</li><li>Under the terms of the deal, OPKO will receive $6M upfront, $6M upon the initiation of a Phase 2 study of RAYALDEE in U.S. dialysis patients, up to $31M in development/regulatory milestones, up to $75M in sales-based milestones and tiered, double-digit royalties on net sales. Japan Tobacco will responsible for all regulatory approvals and commercial activities in Japan.</li><li>Shares are up&nbsp;<font color='green'>1%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300639\" data-linked=\"OPKO inks deal with Japan Tobacco to commercialize Rayaldee in Japan; shares up 1% premarket\" data-tweet=\"$OPK - OPKO inks deal with Japan Tobacco to commercialize Rayaldee in Japan; shares up 1% premarket https://seekingalpha.com/news/3300639-opko-inks-deal-japan-tobacco-to-commercialize-rayaldee-in-japan-shares-up-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3300639-opko-inks-deal-japan-tobacco-to-commercialize-rayaldee-in-japan-shares-up-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300641\" data-ts=\"1507811018\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KNDI\" target=\"_blank\">KNDI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300641-kandi-technologies-fall-after-filing-shelf-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kandi Technologies fall after filing shelf offering</a></h4><ul>     <li>Kandi Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/KNDI' title='Kandi Technologies Group, Inc.'>KNDI</a>) files for a $300M mixed securities shelf offering.</li>     <li>The offering could include common stock, preferred stock, senior debt securities, subordinated debt securities, warrants, rights and units that include any of the securities.</li>     <li><a href=\"https://seekingalpha.com/filing/3725809\" target=\"_blank\">SEC Form S-3</a></li>     <li>Shares of Kandi are <font color='red'>down 6.06%</font> in premarket trading to $7.75.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300641\" data-linked=\"Kandi Technologies fall after filing shelf offering\" data-tweet=\"$KNDI - Kandi Technologies fall after filing shelf offering https://seekingalpha.com/news/3300641-kandi-technologies-fall-after-filing-shelf-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3300641-kandi-technologies-fall-after-filing-shelf-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300631\" data-ts=\"1507809928\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HIMX\" target=\"_blank\">HIMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300631-digitimes-himax-supplying-key-component-of-iphone-x\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Digitimes: Himax supplying key component of iPhone X</a></h4><ul><li>        Digitimes <a href=\"http://www.digitimes.com/news/a20171012PD209.html\" target=\"_blank\">sources</a> say Himax (NASDAQ:<a href='https://seekingalpha.com/symbol/HIMX' title='Himax Technologies, Inc.'>HIMX</a>) is supplying wafer-level optics &#40;WLO&#41; technology to Apple.</li><li>               The WLO tech forms a &ldquo;key component&rdquo; of the iPhone X&rsquo;s Face ID sensor&nbsp;</li><li>               Chip demand could increase in the future as Android phones also shift towards facial recognition technology.&nbsp;</li><li>               Himax shares are&nbsp;<font color='green'>up 1.36%</font>&nbsp;premarket. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3300446-mizuho-downgrades-himax\" target=\"_blank\">Mizuho downgrades Himax</a> (Oct. 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3300631\" data-linked=\"Digitimes: Himax supplying key component of iPhone X\" data-tweet=\"$HIMX - Digitimes: Himax supplying key component of iPhone X https://seekingalpha.com/news/3300631-digitimes-himax-supplying-key-component-of-iphone-x?source=tweet\" data-url=\"https://seekingalpha.com/news/3300631-digitimes-himax-supplying-key-component-of-iphone-x\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>235&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300595\" data-ts=\"1507809889\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VYGR\" target=\"_blank\">VYGR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300595-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Voyager Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/VYGR' title='Voyager Therapeutics'>VYGR</a>) initiated with Outperform rating and $35 (46% upside) price target by Raymond James.</li><li>Spark Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ONCE' title='Spark Therapeutics'>ONCE</a>) initiated with Outperform rating and $96 (11% upside) price target by Raymond James.</li><li>REGENXBIO (NASDAQ:<a href='https://seekingalpha.com/symbol/RGNX' title='REGENXBIO'>RGNX</a>) initiated with Outperform rating and $39 (16% upside) price target by Raymond James.</li><li>Adverum Biotech (NASDAQ:<a href='https://seekingalpha.com/symbol/ADVM' title='Adverum Biotechnologies, Inc.'>ADVM</a>) initiated with Outperform rating and $6 (67% upside) price target by Raymond James.</li><li>Audentes Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/BOLD' title='Audentes Therapeutics'>BOLD</a>) initiated with Outperform rating by Raymond James.</li><li>Quest Diagnostics (NYSE:<a href='https://seekingalpha.com/symbol/DGX' title='Quest Diagnostics Incorporated'>DGX</a>) resumed with a Market Perform rating and $88 (4% downside risk) price target by Wells Fargo.</li><li>Lab Corp (NYSE:<a href='https://seekingalpha.com/symbol/LH' title='Laboratory Corporation of America Holdings'>LH</a>) resumed with an Outperform rating and $175 (17% upside) price target by Wells Fargo.</li><li>Agile Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AGRX' title='Agile Therapeutics, Inc.'>AGRX</a>) resumed with Buy rating and $15 (200% upside) price target by Noble Financial.</li><li>Infinity Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/INFI' title='Infinity Pharmaceuticals, Inc.'>INFI</a>) upgraded to Outperform by Wells Fargo. Shares up&nbsp;<font color='green'>49%</font>&nbsp;premarket.</li><li>Nanostring Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/NSTG' title='NanoString Technologies'>NSTG</a>) downgraded to Market Perform by Cowen and Company after soft preliminary Q3 revenue. Downgraded to Neutral by Janney.</li><li>Trevena (NASDAQ:<a href='https://seekingalpha.com/symbol/TRVN' title='Trevena, Inc.'>TRVN</a>) price target lowered to $7 (195% upside) by H.C. Wainwright after announced restructuring.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300595\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$VYGR $VYGR $ONCE - Premarket analyst action - healthcare https://seekingalpha.com/news/3300595-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3300595-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300629\" data-ts=\"1507809807\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GM\" target=\"_blank\">GM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300629-gm-plays-mexico-wildcard-in-canada\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GM plays Mexico wildcard in Canada</a></h4><ul> <li>General Motors (NYSE:<a href='https://seekingalpha.com/symbol/GM' title='General Motors Company'>GM</a>) <a href=\"http://www.cbc.ca/news/canada/london/gm-canada-chevrolet-production-mexico-ingersoll-cami-strike-1.4351282\" target=\"_blank\">warns</a> Canada's Unifor labor union that it will cut Chevrolet Equinox production in Ontario unless workers call off their extended strike.</li> <li>The automaker is said to be considering a shift of production to Mexico if the walkout isn't called off.</li> <li>Unifor is pushing for a commitment from GM that the Ontario plant will be the main producer of the hot-selling Equinox SUV.</li><li>GM&nbsp;<font color='red'>-1.80%</font>&nbsp;premarket to $44.65.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300629\" data-linked=\"GM plays Mexico wildcard in Canada\" data-tweet=\"$GM - GM plays Mexico wildcard in Canada https://seekingalpha.com/news/3300629-gm-plays-mexico-wildcard-in-canada?source=tweet\" data-url=\"https://seekingalpha.com/news/3300629-gm-plays-mexico-wildcard-in-canada\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300623\" data-ts=\"1507809379\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FLXN\" target=\"_blank\">FLXN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300623-flexion-therapeutics-prices-public-offering-of-common-stock-shares-off-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Flexion Therapeutics prices public offering of common stock; shares off 1% premarket</a></h4><ul> <li>Flexion Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/FLXN' title='Flexion Therapeutics, Inc.'>FLXN</a>) <a href=\"https://seekingalpha.com/pr/16966274-flexion-therapeutics-announces-pricing-public-offering-common-stock\" target=\"_blank\">prices</a>&nbsp;its public offering of 4.8M shares of common stock at a of $25.50 per share yielding gross proceeds of~$122.4M.</li><li>Underwriters over-allotment is an additional&nbsp;720,000&nbsp;shares.</li><li>Net proceeds will be used to fund manufacturing and commercialization of Zilretta, product pipeline development, and for working capital and general corporate purposes. Closing date is October 16, 2017.</li><li>Shares are down&nbsp;<font color='red'>1%</font>&nbsp;premarket on light volume. Yesterday's close was $26.21.</li>       </ul><div class=\"tiny-share-widget\" data-id=\"3300623\" data-linked=\"Flexion Therapeutics prices public offering of common stock; shares off 1% premarket\" data-tweet=\"$FLXN - Flexion Therapeutics prices public offering of common stock; shares off 1% premarket https://seekingalpha.com/news/3300623-flexion-therapeutics-prices-public-offering-of-common-stock-shares-off-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3300623-flexion-therapeutics-prices-public-offering-of-common-stock-shares-off-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300622\" data-ts=\"1507809137\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BTCS\" target=\"_blank\">BTCS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300622-bitcoin-flies-to-new-all-time-high\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bitcoin flies to new all-time high</a></h4><ul><li>The cryptocurrency is<font color='green'> up 8%</font>&nbsp;today to $5,200. Earlier, it touched $5,217.</li><li>Analysts are struggling to explain the surge as there's been no major new news, but it's pretty clear bitcoin has more than shrugged off regulatory crackdowns in China and Russia.</li><li>Crusty economist Ken Rogoff <a href=\"http://www.marketwatch.com/story/price-of-bitcoin-will-collapse-says-economist-who-wrote-the-book-on-currencies-2017-10-09\" target=\"_blank\">earlier this week predicted</a> the technology behind cryptocurrencies will thrive, but the price of bitcoin will collapse as governments move to strangle anonymous payments systems facilitating tax evasion and crime.</li><li>Related tickers: <a href='https://seekingalpha.com/symbol/BTCS' title='BTCS Inc.'>OTCQB:BTCS</a>, <a href='https://seekingalpha.com/symbol/BTSC' title='Bitcoin Services, Inc.'>OTCPK:BTSC</a>, <a href='https://seekingalpha.com/symbol/GBTC' title='Grayscale Bitcoin Trust &#40;BTC&#41;'>OTCQX:GBTC</a>, <a href='https://seekingalpha.com/symbol/GAHC' title='Global Arena Holding, Inc.'>OTCPK:GAHC</a>, <a href='https://seekingalpha.com/symbol/ARSC' title='American Security Resources Corp.'>OTC:ARSC</a>, <a href='https://seekingalpha.com/symbol/MGTI' title='MGT Capital Investments, Inc.'>OTCQB:MGTI</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3300622\" data-linked=\"Bitcoin flies to new all-time high\" data-tweet=\"$BTCS $BTCS $BTSC - Bitcoin flies to new all-time high https://seekingalpha.com/news/3300622-bitcoin-flies-to-new-all-time-high?source=tweet\" data-url=\"https://seekingalpha.com/news/3300622-bitcoin-flies-to-new-all-time-high\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>117&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300621\" data-ts=\"1507809133\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KIDS\" target=\"_blank\">KIDS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300621-orthopediatrics-prices-ipo-13-trading-commences-today\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OrthoPediatrics prices IPO at $13, trading commences today</a></h4><ul><li>OrthoPediatrics (NASDAQ:<a href='https://seekingalpha.com/symbol/KIDS' title='OrthoPediatrics Corp.'>KIDS</a>) <a href=\"https://seekingalpha.com/pr/16966492-orthopediatrics-corp-announces-pricing-initial-public-offering\" target=\"_blank\">prices</a> its IPO of 4M common shares at $13 per share. Underwriters over-allotment is an additional 600K shares. Closing date is October 12. Trading kicks off today.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3189436-orthopediatrics-closing-ipo\" target=\"_blank\">OrthoPediatrics closing in on IPO</a> (June 17, 2016)</li><li><strong>Update</strong>: Shares opened at $18.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300621\" data-linked=\"OrthoPediatrics prices IPO at $13, trading commences today\" data-tweet=\"$KIDS - OrthoPediatrics prices IPO at $13, trading commences today https://seekingalpha.com/news/3300621-orthopediatrics-prices-ipo-13-trading-commences-today?source=tweet\" data-url=\"https://seekingalpha.com/news/3300621-orthopediatrics-prices-ipo-13-trading-commences-today\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300617\" data-ts=\"1507808997\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KPTI\" target=\"_blank\">KPTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300617-karyopharm-and-ono-pharmaceutical-inks-deal-to-commercialize-selinexor-and-kptminus-8602-in\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Karyopharm and Ono Pharmaceutical inks deal to commercialize Selinexor and KPT-8602 in Asia countries; Karyopharm up 8% premarket</a></h4><ul> <li>Karyopharm Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/KPTI' title='Karyopharm Therapeutics Inc.'>KPTI</a>) and Ono Pharmaceutical <a href=\"https://seekingalpha.com/pr/16966388-karyopharm-ono-pharmaceutical-co-ltd-sign-exclusive-license-agreement-develop-commercialize\" target=\"_blank\">enters</a> into an exclusive license agreement for the development and commercialization of <a href=\"https://www.karyopharm.com/pipeline/oral-selinexor-kpt-330/\" target=\"_blank\">Selinexor</a>&nbsp;and <a href=\"https://www.karyopharm.com/pipeline/oral-kpt-8602/\" target=\"_blank\">KPT-8602</a>, a second-generation oral SINE compound for the diagnosis, treatment and/or prevention of all human oncology indications in Japan, South Korea, Taiwan, Hong Kong, and ASEAN countries.</li>    <li>Under the terms of the agreement, Karyopharm will receive (i) a one-time upfront payment of &yen;2.5B (~$22.3M) from ONO and retains all rights to selinexor and KPT-8602 outside the Territory, (ii) up to an additional &yen;19.15B (~$170.7M) if specified future milestones are achieved by ONO, (iii) low double-digit royalties based on future net sales of selinexor and KPT-8602 in the Territory.</li><li>In exchange, ONO will receive exclusive rights to develop and commercialize both compounds in the Territory, at its own cost and expense, and the ability to participate in any global clinical study of selinexor and KPT-8602.</li><li>Shares of Karyopharm are up&nbsp;<font color='green'>8%</font>&nbsp;premarket on light volume.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3300617\" data-linked=\"Karyopharm and Ono Pharmaceutical inks deal to commercialize Selinexor and KPT-8602 in Asia countries; Karyopharm up 8% premarket\" data-tweet=\"$KPTI - Karyopharm and Ono Pharmaceutical inks deal to commercialize Selinexor and KPT-8602 in Asia countries; Karyopharm up 8% premarket https://seekingalpha.com/news/3300617-karyopharm-and-ono-pharmaceutical-inks-deal-to-commercialize-selinexor-and-kptminus-8602-in?source=tweet\" data-url=\"https://seekingalpha.com/news/3300617-karyopharm-and-ono-pharmaceutical-inks-deal-to-commercialize-selinexor-and-kptminus-8602-in\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:49 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300615\" data-ts=\"1507808322\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DPZ\" target=\"_blank\">DPZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300615-comparable-sales-impress-dominos-pizza\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Comparable sales impress at Domino&#39;s Pizza</a></h4><ul> <li>Domino's Pizza (NYSE:<a href='https://seekingalpha.com/symbol/DPZ' title='Domino&#39;s Pizza, Inc.'>DPZ</a>) tops <a href=\"https://seekingalpha.com/pr/16966552-dominos-pizza-announces-third-quarter-2017-financial-results\" target=\"_blank\">Q3</a> estimates as U.S. comparable store sales shot up 8.4% vs. +6.5% consensus.</li> <li>International comparable sales were up 5.1% during the quarter vs. +3.2% consensus.</li> <li>Global retail sales were up 14.5% as a higher store count contributed.</li> <li>Net income rose 19% Y/Y as the same store sales growth and a new equity-based compensation accounting standard factored in.</li> <li>Domino's ended the quarter ith a store count of 14,434, up 217 Q/Q on a net basis.</li> <li>Shares of Domino's Pizza are <font color='red'>down 0.59%</font> in premarket trading.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3300612-dominos-pizza-beats-0_04-beats-revenue\" target=\"_blank\">Domino's Pizza beats by $0.04, beats on revenue</a> (Oct. 12)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300615\" data-linked=\"Comparable sales impress at Domino&#39;s Pizza\" data-tweet=\"$DPZ - Comparable sales impress at Domino&#39;s Pizza https://seekingalpha.com/news/3300615-comparable-sales-impress-dominos-pizza?source=tweet\" data-url=\"https://seekingalpha.com/news/3300615-comparable-sales-impress-dominos-pizza\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300611\" data-ts=\"1507807237\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ONCE\" target=\"_blank\">ONCE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300611-trading-halted-in-spark-therapeutics-pending-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trading halted in Spark Therapeutics pending news</a></h4><ul><li>Nasdaq has suspended trading in Spark Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ONCE' title='Spark Therapeutics'>ONCE</a>) pending the release of news. Today is the FDA Ad Com review for LUXTURNA (voretigene neparvovec).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3300337-fda-ad-com-review-tomorrow-sparks-luxturna-vision-loss-due-type-retinal-dystrophy\" target=\"_blank\">FDA Ad Com review tomorrow for Spark's Luxturna for vision loss due to type of retinal dystrophy</a> (Oct. 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3300611\" data-linked=\"Trading halted in Spark Therapeutics pending news\" data-tweet=\"$ONCE - Trading halted in Spark Therapeutics pending news https://seekingalpha.com/news/3300611-trading-halted-in-spark-therapeutics-pending-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3300611-trading-halted-in-spark-therapeutics-pending-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300610\" data-ts=\"1507807060\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JILL\" target=\"_blank\">JILL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300610-j-jill-on-watch-after-rbc-capital-loses-confidence\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">J. Jill on watch after RBC Capital loses confidence</a></h4><ul> <li>RBC Capital Markets lowers J. Jill Group (NYSE:<a href='https://seekingalpha.com/symbol/JILL' title='J. Jill Group, Inc.'>JILL</a>) to a Sector Perform rating after having the mall retailer set at Outperform.</li> <li>The investment firm's price target of $7 reps 30% downside potential for shares.</li> <li>J. Jill is <font color='red'>down 38%</font> in premarket trading, although only a few hundred shares have been swapped so the move may be overstated.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300610\" data-linked=\"J. Jill on watch after RBC Capital loses confidence\" data-tweet=\"$JILL - J. Jill on watch after RBC Capital loses confidence https://seekingalpha.com/news/3300610-j-jill-on-watch-after-rbc-capital-loses-confidence?source=tweet\" data-url=\"https://seekingalpha.com/news/3300610-j-jill-on-watch-after-rbc-capital-loses-confidence\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}